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Abstract 
 This thesis is comprised of 3 chapters involving studies evaluating live yeast and yeast 
extracts with or without the addition of pharmacological levels of Zn, feeding sows live yeast 
and a yeast extract and following their offspring into the nursery where progeny were fed 
varying inclusions of yeast additives and direct fed microbials (DFM). Chapter 1 involved 360 
weanling barrows to determine the effects of feeding live yeast and yeast extracts with or without 
pharmacological Zn on nursery pig growth performance, fecal dry matter (DM), and 
antimicrobial susceptibilities of fecal E.coli. The results suggest that feeding pharmacological Zn 
for 21-d post-weaning is an effective strategy to optimize growth performance, economic 
criteria, and increase fecal DM for the first few days following weaning. Although all isolates 
were classified as susceptible to ciprofloxacin, the minimal inhibitory concentration (MIC) of 
fecal E.coli tended to be increased when pigs were fed pharmacological levels of Zn but no 
difference was observed to the remaining thirteen antimicrobials that were evaluated. Thus, the 
short-term use of pharmacological levels of Zn did not increase antimicrobial resistance (AMR). 
There was no benefit for any of the growth, economic, fecal DM, or AMR response criteria when 
live yeast and yeast extracts were included in the diets. Chapter 2 involved three batch-farrowing 
groups where 80 sows were used to determine the effects of feeding live yeast and a yeast 
extract’s impact on sow and litter performance. One of the three sow groups (27 sows) were used 
to determine the yeast additives impact on the antimicrobial susceptibility of sow fecal E.coli. 
The results suggest that feeding live yeast and a yeast extract, from d 110 of gestation through 
lactation, may increase sow feed intake but had no impact on any other sow or litter performance 
criteria. A diet by sampling day interaction revealed that fecal E.coli isolates gained resistance to 
the antimicrobial cefoxitin over time when the yeast additives were included in the diet, but the 
main effect of diet had no impact on any of the fourteen antibiotics tested. Chapter 3 consisted of 
two experiments which used 670 weaned pigs to evaluate previous sow treatment (control vs 
yeast additives) and nursery diets with varying combinations of yeast additives and DFM.  In 
Exp. 1, subsequent offspring from one of the sow groups in chapter 2 were fed either a control 
diet or a diet that contained live yeast and yeast extracts to evaluate growth performance and the 
AMR patterns of fecal E.coli. In Exp 2., subsequent offspring from one of the sow groups in 
chapter 2 were fed either a control diet, a diet containing yeast extracts (DFM 1), or a diet with 
Bacillus spp. and yeast extracts (DFM 2). Results from both studies suggest that feeding sows 
yeast additives from d 110 of gestation through lactation can improve growth performance of 
their offspring in the nursery. In Exp. 1, feeding live yeast and yeast extracts in the nursery 
appeared to hinder growth performance. However, in Exp. 2, pigs that were fed DFM 2 reported 
optimized growth in the late nursery period. In Exp 1., results suggest that progeny from sows 
that were fed yeast might increase the potential of fecal E.coli MIC to nalidixic acid, 
ciprofloxacin, and gentamicin. Yet, feeding live yeast and yeast extracts in the nursery may 
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CHAPTER 1- Live yeast and yeast extracts with and without 
pharmacological levels of zinc on nursery pig growth performance 
and antimicrobial susceptibilities of fecal Escherichia coli 
 
 Abstract 
A total of 360 weanling barrows (Line 200  400, DNA, Columbus NE; initially 5.6 ± 
0.03 kg) were used in a 42-d study to evaluate yeast-based pre- and probiotics (Phileo by 
Lesaffre, Milwaukee, WI) in diets with or without pharmacological levels of Zn on growth 
performance and antimicrobial resistance (AMR) patterns of fecal Escherichia coli. Pens were 
assigned to 1 of 4 dietary treatments with 5 pigs per pen and 18 pens per treatment. Dietary 
treatments were arranged in a 2 × 2 factorial with main effects of yeast-based pre- and probiotics 
(none vs. 0.10% ActiSaf Sc 47 HR+, 0.05% SafMannan, and 0.05% NucleoSaf from d 0 to 7, 
then concentrations were lowered by 50% from d 7 to 21) and pharmacological levels of Zn (110 
vs. 3,000 mg/kg from d 0 to 7, and 2,000 mg/kg from d 7 to 21 with added Zn provided by ZnO). 
All pigs were fed a common diet from d 21 to 42 post-weaning. There were no yeast  Zn 
interactions or effects from yeast additives observed on any response criteria. From d 0 to 21, 
and 0 to 42, pigs fed pharmacological levels of Zn had increased (P < 0.001) ADG and ADFI. 
The dietary addition of Zn improved (P < 0.05) most economic criteria. Fecal samples were 
collected on d 4, 21, and 42 from the same three pigs per pen for fecal dry matter (DM) and 
AMR patterns of E.coli. On d 4, pigs fed pharmacological levels of Zn had greater fecal DM (P 
= 0.043); however, no differences were observed on d 21 or 42. E.coli was isolated from fecal 
samples and the microbroth dilution method was used to determine the minimal inhibitory 
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concentrations (MIC) of E.coli isolates to 14 different antimicrobials. Isolates were categorized 
as either susceptible, intermediate, or resistant based on Clinical and Laboratory Standards 
Institute (CLSI) guidelines. The addition of pharmacological levels of Zn had a tendency (P = 
0.051) to increase the MIC values of ciprofloxacin; however, these MIC values were still well 
under the CLSI classified resistant breakpoint for Ciprofloxacin. There was no evidence for 
differences (P > 0.10) for yeast additives or Zn for AMR of fecal E.coli isolates to any of the 
remaining antibiotics. In conclusion, pharmacological levels of Zn improved ADG, ADFI, and 
economic criteria and all isolates were classified as susceptible to ciprofloxacin although the 
MIC of fecal E.coli tended to be increased. Thus, the short-term use of pharmacological levels of 
Zn did not increase antimicrobial resistance. There was no response observed from live yeast and 
yeast extracts for any of the growth, fecal DM, or AMR of fecal E.coli criteria. 
 
 





ADFI: Average daily feed intake 
ADG: Average daily gain 
AMR: Antimicrobial resistance 
ATCC: American Type Culture Collection 
BW: Body weight 
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CFU: Colony-forming unit 
CLSI: Clinical and Laboratory Standards Institute 
CP: Crude protein 
DFM: Direct-fed microbial 
DM: Dry matter 
G:F: Gain-to-feed ratio 
IOFC: Income over feed cost 
ME: Metabolizable energy 
MIC: Minimal inhibitory concentration  
NARMS: National Antimicrobial Resistance Monitoring System  
NE: Net energy 
NRC: National Research Council 
PCR: Polymerase chain reaction 
PWD: Post-weaning diarrhea  
SCFA: Short-chain fatty acid 
SEM: Standard error of the mean 
SID: Standardized ileal digestible 
STTD: Standardized total tract digestible 




Feeding pharmacological levels (2,000 to 3,000 mg/kg) of Zn in the early nursery has 
been an industry-wide practice to alleviate the lag in performance and control occurrences of 
post-weaning diarrhea (PWD; Jacela et al., 2010b). However, feeding pharmacological levels of 
Zn has become a concern for AMR to antibiotics of importance to human and animal medicine 
(Nguyen et al., 2019; Muurinen et al., 2021). Use of these minerals is restricted in some 
countries due to their impact on environmental buildup and their capability to create a favorable 
environment for gut bacteria to acquire and transmit AMR genes (Yazdankhah et al., 2014; 
Zhang et al., 2019; Bonetti et al., 2021). 
 One potential replacement strategy for pharmacological levels of added Zn in the early 
nursery is the use of pre- and probiotics. Prebiotics are substrates that selectively stimulate the 
growth of beneficial microbes in the gastrointestinal tract (Jacela et al., 2010a). Feeding 
probiotics can alter the gut’s microflora by introducing live cultures of beneficial 
microorganisms into the digestive tract and can aid in competitively exclude or suppress 
pathogens (Liao and Nyachoti, 2017). The improved microbial profile in the gut may allow for 
more protection against enteric diseases while subsequently improving growth performance 
(Doyle, 2001; Jacela et al., 2010a). For example, a live yeast strain of Saccharomyces cerevisiae 
and β-glucan derived from yeast cell walls have been shown to reduce the shedding of 
enterotoxigenic E.coli, shorten periods of diarrhea, and increase body weight in the early nursery 
period (Stuyven et al., 2009; Trckova et al., 2014). Further research suggests that dietary addition 
of live yeast maintains intestinal villi integrity and helps alleviate inflammation caused by enteric 
pathogens (Che et al., 2017). Amachawadi et al. (2018) found that probiotics may reduce the 
prevalence and proliferation of AMR of gastrointestinal bacteria, making pre- and probiotics an 
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alternative of interest to high levels of Zn. Our hypothesis was that the additions of a live yeast 
(probiotic) and yeast extracts (prebiotics) would provide equal, if not additive, growth responses 
to added Zn without promoting AMR in nursery pigs. Thus, the objective of this study was to 
determine the effects of pharmacological levels of Zn with or without the addition of the live 
yeast Saccharomyces cerevisiae strain NCYC Sc 47 and yeast-based prebiotics derived from S. 
cerevisiae on nursery pig growth performance and AMR patterns of E.coli isolated from nursery 
pig fecal material. 
 
 Materials and Methods 
 General  
The Kansas State University Institutional Animal Care and Use Committee approved the 
protocol used in this experiment. The study was conducted at the Kansas State University 
Segregated Early Weaning Facility in Manhattan, KS. The facility has two identical barns that 
are completely enclosed, environmentally controlled, and mechanically ventilated. Treatments 
were equally represented in each barn. Each pen contained a 4-hole, dry self-feeder and a cup 
waterer to provide ad libitum access to feed and water. Pens (1.3  1.3 m) had metal tri-bar 
floors and allowed approximately 0.33 m2/pig.  
 
 Animals and treatment structure 
A total of 360 barrows (Line 200  400; DNA, Columbus, NE; initial BW 5.6 ± 0.03 kg) 
were used in a 42-d study with 5 pigs per pen and 18 pens per treatment (9 pens per barn). Upon 
arrival to the research site, pigs were randomly assigned to pens. Pens were then assigned to 1 of 
6 
4 dietary treatments in a randomized complete block design with pens blocked by BW. During 
the study three pigs were removed due to illness or injury. 
Dietary treatments were arranged in a 2 × 2 factorial with main effects of yeast-based 
pre- and probiotics (none vs. 0.10% ActiSaf Sc 47 HR+, 0.05% SafMannan, and 0.05% 
NucleoSaf from d 0 to 7, then concentrations were lowered by 50% from d 7 to 21) and 
pharmacological levels of Zn (110 mg/kg vs. 3,000 mg/kg from d 0 to 7 and 2,000 mg/kg from d 
7 to 21; added Zn provided by ZnO; Table 1-1). The live S. cerevisiae strain NCYC Sc 47 
(ActiSaf Sc 47 HR+; Phileo by Lesaffre, Milwaukee, WI) served as the yeast-based probiotic. 
The yeast-based prebiotics included a yeast cell wall fraction with concentrated mannan-
oligosaccharides and β-glucans from S. cerevisiae (SafMannan; Phileo by Lesaffre) and a yeast 
extract containing ≥ 6% unbound nucleotides from S. cerevisiae (NucleoSaf; Phileo by Lesaffre).  
 
 Diet preparation 
  Pigs were fed phase 1 diets from placement until d 7 and then offered phase 2 diets from 
d 7 to 21 (Table 1-1). A common phase 3 diet, without yeast additives or pharmacological levels 
of ZnO, was fed to all pigs from d 21 to 42. Phase 1 diets were formulated to a 1.40% 
standardized ileal digestible (SID) Lys and phase 2 and 3 diets were formulated to a 1.35% SID 
Lys. All other nutrients were formulated to meet or exceed National Research Council (NRC, 
2012) requirement estimates. Phase 1 and 2 diets were manufactured at the Kansas State 
University Poultry Unit (Manhattan, KS) and the common phase 3 diet was manufactured at a 
commercial feed mill (Hubbard Feeds; Beloit, KS). Diets in all three phases were fed in meal 
form. Pens of pigs were weighed and feed disappearance recorded weekly during the course of 
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this study to determine average daily gain (ADG), average daily feed intake (ADFI), and gain-to-
feed ratio (G:F). 
 
 Chemical analysis 
Phase 1 and 2 diet samples were collected at manufacturing and phase 3 diets were 
collected from every fourth 23-kg bag using a feed probe to collect a representative sample for 
each respective diet and phase. Complete diet samples were stored at -20C until they were 
homogenized, subsampled, and submitted for analysis. Duplicate composite samples per dietary 
treatment were analyzed (Ward Laboratories; Kearney, NE) for dry matter (method 935.29; 
AOAC International 2019), crude protein (method 990.03; AOAC International, 2019), and zinc 
(Campbell and Plank, 1991). Separate composite samples per dietary treatment were analyzed 
for active live yeast (Analabs; Fulton, IL; method 997.02; AOAC International, 1998) for phases 
1 and 2 (Table 1-2).  
 
 Economics 
 Total feed cost per pig, cost per kg of gain, revenue, and income over feed cost (IOFC) 
were calculated to evaluate the economics behind including yeast additives and ZnO. Feed cost 
per pig placed was determined by multiplying total feed intake by diet cost then divided by 
number of pigs placed. Feed cost per kg of gain was calculated by dividing the total feed cost per 
pig by the total weight gained per pig. Revenue per pig placed was determined by total gain 
times $1.47/kg carcass price then multiplied by the assumed dressing percentage (75%) in order 
to convert to a live price. Income over feed cost was calculated using revenue per pig placed 
minus feed cost per pig placed. For all economic evaluations, the following ingredients prices 
8 
were used: corn = $7.06/bushel ($278/metric ton); soybean meal = $404/metric ton; L-Lys HCl = 
$1.76/kg; DL-methionine = $4.85/kg; MHA =$4.96/kg; L-threonine = $2.23/kg; L-tryptophan = 
$8.80/kg; L-valine = $5.10/kg; ZnO = $2.41/kg; ActiSaf Sc 47 HR+ = $6.17/kg; SafMannan = 
$3.09/kg; and NucleoSaf = $18.08/kg.  
 
 Fecal collection 
Fecal samples were collected on d 4, 21, and 42 of the experiment for antimicrobial 
susceptibility and resistance profiles of E.coli and fecal dry matter (DM) analysis. Fecal samples 
were collected directly from the rectum of the same three randomly selected pigs from each pen 
and pooled by pen to form one composite sample. Fecal samples were collected using a sterile, 
single-use cotton tipped applicator (Fisher Healthcare, Pittsburgh, PA) and were stored in a 
clean, single-use zipper storage bag. Samples were immediately transported on ice to the Kansas 
State University College of Veterinary Medicine for bacterial isolation and antimicrobial 
susceptibility testing of E.coli. The remaining contents, after samples were collected for E.coli 
isolation, were stored at -20C until fecal dry matter analysis. Fecal samples were pooled by pen, 
within day of collection, and dried at 55C in a forced air oven for 48 hours. Fecal DM was 
calculated as:  
Fecal DM % =
Dry sample weight at 48 h –  pan weight
Initial wet sample weight −  pan weight
× 100 
 
 E.coli isolation and identification 
Approximately, 1 g of pooled fecal sample was suspended in 9 mL of phosphate-buffered 
saline and vortexed for a minute. Fifty microliters of the fecal suspension were spread-plated 
onto a MacConkey agar plate (Becton Dickinson, Sparks, MD) for the isolation of E.coli. Two 
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lactose-fermenting colonies were picked from each plate, individually streaked onto a blood agar 
plate (Remel, Lenexa, KS) and incubated at 37° C for 24 h. Spot indole test was done and indole-
positive isolates were stored in cryo-protect beads (Cryocare, Key Scientific Products, Round 
Rock, TX) at −80°C. Species confirmation of E.coli was by polymerase chain reaction (PCR) for 
uidA and clpB genes. 
 
 Antimicrobial susceptibility testing of E.coli isolates 
Antimicrobial susceptibility testing was accomplished on one E.coli isolate per fecal 
sample recovered on days 4, 21, and 42. The microbroth dilution method as outlined by the 
Clinical and Laboratory Standards Institute (CLSI, 2018) was used to determine the minimal 
inhibitory concentrations (MIC) of 14 antibiotics. The antimicrobials tested included: 
amoxicillin/clavulanic acid, ampicillin, azithromycin, cefoxitin, ceftiofur, ceftriaxone, 
chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfisoxazole, 
tetracycline, and trimethoprim/sulfamethoxazole. Each isolate, stored in cryo-protect beads, was 
streaked onto a blood agar plate and incubated at 37 °C for 24 h. Individual colonies were 
suspended in demineralized water (Trek Diagnostic Systems, Cleveland, OH) and turbidity was 
adjusted to 0.5 McFarland turbidity standard. Then, 10 µL of the bacterial inoculum was added 
to Mueller–Hinton broth (11 ml) and vortexed to mix. A Sensititre automated inoculation 
delivery system (Trek Diagnostics Systems) was used to dispense 100 µL of the culture into 
National Antimicrobial Resistance Monitoring System (NARMS) panel plates designed for 
Gram-negative (CMV3AGNF, Trek Diagnostic Systems) bacteria. Escherichia coli ATCC 
25922 (American Type Culture Collection, Manassas, VA) strain was included as quality 
control. Plates were incubated at 37 °C for 18 h and bacterial growth was assessed using 
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Sensititre ARIS and Vizion systems (Trek Diagnostic Systems). Clinical and Laboratory 
Standards Institute (CLSI, 2018; Table 1-3) guidelines were used to classify each isolate as 
susceptible, intermediate, or resistant according to the breakpoints established for each 
antimicrobial.  
 
 Statistical analysis 
Growth, fecal dry matter, and economics. Growth performance, fecal dry matter, and 
economics data were analyzed using the nlme package of R (Version 4.0.0, R Foundation for 
Statistical Computing, Vienna, Austria) as a randomized complete block design with body 
weight (BW) and barn serving as the blocking factor and pen as the experimental unit. The main 
effects of yeast-derived pre- and probiotics and pharmacological levels of zinc, as well as their 
interactions, were tested. Fecal DM was analyzed using repeated measures analysis considering 
the multiple measures taken on the same experimental unit over the study. Differences between 
treatments were considered significant at P ≤ 0.05 and marginally significant at 0.05 < P ≤ 0.10. 
Antimicrobial susceptibility. For each of the 14 antimicrobials, MIC data were 
summarized with appropriate descriptive statistics by treatment group at each sampling day. 
Because all isolates were resistant, MICs of tetracycline were excluded from the statistical 
analysis. The MIC data of the remaining antimicrobials were analyzed using the linear mixed 
model. To better achieve model assumptions, data underwent natural log transformation before 
statistical modeling. Statistical analysis was performed using the MIXED procedure of SAS 
(version 9.4; Cary, NC) with option DDFM=KR in the MODEL statement. Fixed effects of the 
model included Zn, yeast, sampling time, and their second-and third-order interactions. Random 
effects included block and pen. Treatment effect was assessed via back-transformed least squares 
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means, i.e. geometric means of the MIC values. The variance-covariance structure of pen was 
taken as either compound symmetry, first-order autoregressive or unstructured according to the 
model fitting criteria.  
 
 Results 
 Growth performance 
There were no interactions observed between the dietary addition of pharmacological 
levels of Zn and yeast-based pre- and probiotics (Table 1-4 & Table 1-5). In phases 1 (d 0 to 7) 
and 2 (d 7 to 21), pigs fed pharmacological levels of Zn had increased (P < 0.05) ADG, ADFI, 
and heavier d 7 and 21 BW compared to pigs fed the diet containing basal trace mineral amounts 
of Zn (110 mg/kg). Pigs that were fed diets containing ZnO had improved (P < 0.001) G:F in 
phase 1 while the dietary addition of live yeast and yeast extracts had a tendency (P = 0.077) for 
improved G:F in phase 1, but the addition of live yeast and yeast extracts had no other effects on 
any further growth performance criteria in this study.  
For the experimental period (d 0 to 21), pigs fed pharmacological levels of Zn had 
increased (P < 0.001) ADG and ADFI leading to increased (P < 0.001) d 21 BW. However, there 
was no evidence for difference (P > 0.10) in G:F between those fed diets with or without 
pharmacological levels of Zn. 
During the common period (d 21 to 42), pigs previously fed pharmacological levels of Zn 
had increased (P = 0.002) BW on d 42 compared those fed diets without added Zn. There was no 
evidence for statistical difference (P > 0.10) between any of the previous treatment combinations 
on any of the remaining growth criteria. 
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For the overall study (d 0 to 42), pigs fed pharmacological levels of Zn had increased (P 
< 0.05) ADG, ADFI, G:F and heavier BW. There were no differences observed for pigs fed 
yeast-based pre- and probiotics. 
 
 Economics  
 No interactions between the addition of live yeast and pharmacological Zn were observed 
for any economic criteria (Table 1-4). There was a tendency (P = 0.062) for increased feed cost 
per pig when yeast additives were included in the diet compared to a diet without yeast; 
however, there was no evidence for difference (P = 0.923) for feed cost per kg of gain. There 
was no statistical difference (P > 0.10) between diets with or without yeast-based pre- and 
probiotics, pigs fed yeast had a numerical increase in revenue (+$0.53; Table 5) and IOFC 
(+$0.19; Table 1-5). Pigs fed pharmacological levels of Zn, provided by ZnO, had a tendency (P 
= 0.076) for increased feed cost per pig compared to those fed diets without added ZnO; yet, pigs 
fed pharmacological levels of Zn had lower (P = 0.014) feed cost per kg of gain. Furthermore, 
pigs fed added ZnO had increased (P < 0.005) revenue (+$0.99) and IOFC (+$0.67) compared to 
pigs diets without pharmacological Zn (Table 1-5).  
 
 Fecal dry matter  
There were no interactions observed between the dietary addition of pharmacological 
levels of Zn and yeast-based pre- and probiotics or for the main effect of yeast additives for fecal 
dry matter. On d 4, pigs fed 3,000 mg/kg of Zn had greater (P = 0.043) fecal DM than those 
without added Zn (Table 1-5). However, no differences were observed on d 21 or 42 between 
any of the dietary treatments for fecal DM.  
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 Antimicrobial susceptibility   
There were no two-way or three-way interactions observed for any of the antimicrobials 
among the E.coli isolates tested (Table 1-6). Thus, MIC values of fecal E.coli isolates in 
response to the inclusion of yeast-based pre- and probiotics, pharmacological levels of Zn, and 
sampling day were further explored (Table 1-7).  
 All fecal E.coli isolates were susceptible to azithromycin, ciprofloxacin, nalidixic acid, 
sulfisoxazole, and trimethoprim/sulfamethoxazole at all three sampling time points (d 4, 21, and 
42) regardless of the inclusion of live yeast and yeast extracts or pharmacological levels of Zn. 
Regardless of diet or sampling day, fecal E.coli isolates were intermediate to 
amoxicillin:clavulanic acid, ampicillin, cefoxitin, ceftiofur, and chloramphenicol. E.coli isolates 
from all dietary treatments were resistant to streptomycin at all three sampling time points. 
Interestingly, fecal E.coli was susceptible to gentamicin on d 4 and 42 but intermediate on d 21. 
On d 4 and 21, fecal E.coli isolates were considered intermediate to ceftriaxone but were 
resistant on d 42.  
 There was evidence for increased (P < 0.05) MIC values over time for ampicillin, 
cefoxitin, ceftriaxone, ciprofloxacin, nalidixic acid, and sulfisoxazole. Values for azithromycin 
and trimethoprim/sulfamethoxazole decreased (P < 0.05) from d 4 to 21 but then increased (P < 
0.05) from d 21 to 42. Chloramphenicol MIC values increased (P < 0.05) from d 21 to 42 with d 
4 values being intermediate while MIC values for gentamicin increased (P < 0.05) from d 4 to 21 
with d 42 values being intermediate.  
 The MICs of antimicrobials were not affected by the dietary addition of yeast-based pre- 
and probiotics. Only fecal E.coli isolated from pigs fed pharmacological levels of Zn from d 0 to 
21 had a marginally significant effect (P = 0.051) where the AMR to ciprofloxacin was higher 
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compared to those that were not fed added Zn. However, all median MICs were still well under 
the CLSI (2018) resistant breakpoint for ciprofloxacin. 
 
 Discussion 
The dietary addition of prebiotics provides a substrate that is indigestible by the host but 
is fermented by gut bacteria, thereby selectively stimulating the growth of a beneficial microbial 
population in the gastrointestinal tract (Gibson et al., 2004). Inulin, lactulose, fructo-
olgosaccharides, and transgalacto-oligosaccharides are some of the most common prebiotics 
used in swine diets because favorable gut bacteria can ferment them readily and produce short-
chain fatty acids (SCFA; Gibson et al., 2004; Menegat et al., 2019b). In this study, we evaluated 
prebiotic benefits of a yeast cell wall fraction with concentrated mannan-oligosaccharides and β-
glucans derived from S. cerevisiae (SafMannan; Phileo by Lesaffre) and a yeast extract 
containing ≥ 6% unbound nucleotides derived from S. cerevisiae (NucleoSaf; Phileo by 
Lesaffre). Feeding a probiotic, a live microorganism, can alter the gut’s microflora by 
introducing live cultures of favorable microbes into the digestive tract that can aid in competitive 
exclusion or suppression of pathogens (Cameron and McAllister, 2019). The production of lactic 
acid and SCFA can lower intestinal pH; thus, promoting intestinal villi growth and epithelial 
integrity, which may improve nutrient digestibility and nutrient absorption and suppress enteric 
pathogens to mitigate subclinical infections (Liao and Nyachoti, 2017; Cameron and McAllister, 
2019). Most probiotics can be categorized into one of three groups: Bacillus, lactic acid 
producing bacteria, or yeasts (Stein and Kil, 2006). The live yeast S. cerevisiae strain NCYC Sc 
47 (ActiSaf Sc 47 HR+; Phileo by Lesaffre) was evaluated in the present study as the probiotic 
source. Live yeast (probiotics) and yeast extracts (prebiotics) are of particular interest due to the 
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β-glucans and α-mannans found in yeast cell walls along with unbound nucleotides. Yeast cell 
walls may improve the colonization of good bacteria in the gut by preventing the binding of 
enteric pathogens to the intestinal mucosa. Additionally, live yeast and yeast cell walls have the 
potential to improve immunity (Perez-Sotelo et al., 2011; Zanello et al., 2011; Badia et al., 
2012), bind toxins (Kogan and Kocher, 2007), reduce the instances of enteric infections (Kiarie 
et al., 2011; Che et al., 2017; Trevisi et al., 2017), thus contributing to improved growth 
performance in the nursery (Shen et al., 2009; Kiros et al., 2018). Furthermore, live yeast and 
yeast extracts contain free nucleotides. Feeding unbound nucleotides in the early nursery has 
demonstrated to increase feed intake, improve intestinal integrity of the epithelial lining, and 
reduce periods of diarrhea by promoting beneficial microbiota colonization in the gastrointestinal 
tract (Stein and Kil, 2006; Liu et al., 2018). While many studies have shown positive impacts 
from the dietary addition of pre- and probiotics due to the modulation of the gut’s microbial 
population and host immunity, there are still inconsistent results on the impact of growth criteria 
(Zimmerman et al., 2016).  
Zinc is an imperative micronutrient for many physiological body functions. Some 
functions include enzyme performance for metabolism, digestion, and cellular signaling, normal 
skin accretion, along with proper body maintenance and reproductive development (Reese and 
Hill, 2010; Bonetti et al., 2021). The NRC (2012) requirements for Zn is 26.6 to 46.8 mg/kg of 
Zn for a 4 to 12 kg pig. Flohr et al. (2016) found that the average for Zn inclusion in the United 
States swine industry was 3,032 mg/kg Zn and 2,081 mg/kg Zn in phase 1 (weaning to 7 kg BW) 
and phase 2 (7 to 11 kg BW) diets, respectively. These pharmacological levels of Zn are well 
above the pig’s physiological requirement; however, elevated levels of Zn in the diet, for 10 to 
21 days immediately following weaning, has been proven to have positive implications on 
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growth performance and controlling PWD in a young pig. We observed increased ADG, ADFI, 
G:F, BW, and fecal DM on d 4 post-weaning when weaned pigs were fed 3,000 mg/kg Zn in 
phase 1 and 2,000 mg/kg Zn in phase 2 with the added Zn provided by ZnO. Many studies 
support the positive attributes that pharmacological Zn, in the form of ZnO, has on improved 
growth, increased intake, and reduced occurrence of PWD (Hill et al., 2000; Reese and Hill, 
2010; Sales, 2013). Other forms of Zn (ZnSO4 and Zn-Lys) have shown inconsistent results 
when fed at pharmacological levels (Hahn and Baker, 1993; Bonetti et al., 2021). Zinc oxide has 
unique modes of action which include antimicrobial tendencies, antioxidant properties, improved 
digestion and nutrient absorption because of increased secretion of ghrelin in the stomach and 
digestive enzymes in the pancreas, as well as improved intestinal epithelial integrity, hence 
improved gut barrier function and enhanced immune responses (Liu et al., 2018; Bonetti et al., 
2021). Even though ZnO has proved to be a beneficial additive in the early nursery for growth 
and controlling PWD, alternative feeding strategies are being explored.  
 One such strategy is the use of yeast-based pre- and probiotics. In the present study, we 
observed a tendency for improved G:F immediately following weaning from d 0 to 7 but no 
further statistical impact from the dietary addition of live yeast and yeast extracts for any of the 
remaining growth criteria during the experimental, post-treatment, or overall study period. The 
lack of statistical growth response from added yeast-based pre- and/or probiotics is consistent 
with results found by Perez-Sotelo et al. (2011), Trevisi et al. (2015), and Williams et al. (2016). 
However, others have found that supplementing the live yeast S. cerevisiae has increased growth 
parameters such as ADG, ADFI, and BW (Shen et al., 2009; Kiarie et al., 2011; Kiros et al., 
2018). As previously discussed, the results from the dietary addition of yeast additives are 
inconsistent and variable (Zimmerman et al., 2016; Liu et al., 2018). For example, in two 
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experiments conducted by van Heughten et al. (2003), there was no added benefit for any growth 
criteria when pigs were fed S. cerevisiae in the first experiment; however, in the second 
experiment they observed heavier BW and increased ADG when the live yeast was 
supplemented with antibiotics and pharmacological Zn and Cu compared to when yeast was not 
included. The variability in literature regarding growth performance and inclusion of yeast 
additives can be attributed to multiple factors. Some of these factors may include yeast strain, 
inclusion rate, and/or the duration of feeding the yeast additive(s), product inconsistency, as well 
as external factors such as genetics, herd health status, and general stockmanship (Liao and 
Nyachoti, 2017).  
The five main concerns to the dietary addition of pharmacological levels of ZnO are 
environmental pollution, co-selection of resistance to antibiotics that are important to human and 
animal medicine, heavy metal tolerance of gut bacteria, microflora modification in the gut, and 
Zn toxicity to the pig (Bonetti et al., 2021). Because of these concerns, the European Union had 
put a ban on feeding pharmacological levels of Zn beginning in June of 2022 with the legal limit 
being 150 mg/kg of Zn in a complete feed (EMA, 2017). In a study on the effect of heavy metals 
in liquid swine manure on AMR, Hölzel et al. (2012) observed that Zn was linked to the 
resistance of doxycycline, tetracycline, piperacillin, ampicillin, and multi- drug resistant E.coli. 
Multi-drug resistance is characterized when the bacteria is resistant to three or more 
antimicrobial classes (Schwarz et al., 2010). Furthermore, Bednorz et al. (2013) observed that 
18.6% of E.coli isolates, cultured from digesta originating from the ileum of nursery pigs, were 
multi-drug resistant when pigs were fed 2,500 mg/kg of Zn while no multi-drug resistant isolates 
were identified for pigs fed a diet containing 50 mg/kg of Zn. There are several other studies that 
report increased prevalence of AMR genes when pharmacological Zn is included in the diet 
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(Slifierz et al., 2015; Ciesinksi et al., 2018; Muurinen et al., 2021). Conversely, we observed that 
the inclusion of pharmacological Zn had little impact on the AMR to 13 of the 14 antibiotics 
tested. When MIC values were averaged across the three sampling time points, fecal E.coli 
tended to be more resistant to ciprofloxacin when pigs were fed pharmacological levels of Zn for 
the first 21 d post-weaning; however, all isolates were still considered susceptible based off its 
CLSI (2018) breakpoint. Ciprofloxacin is a fluoroquinolone class of antimicrobial that is not 
approved for use in food animals. However, ciprofloxacin is a broad-spectrum antibiotic in 
human medicine used to treat both Gram-negative and Gram-positive bacterial infections (Davis 
et al., 1996).  
To our knowledge, there is limited data evaluating yeast-based pre- and probiotics’ 
impact on the AMR of gut bacteria. However, Ouwehand et al. (2016) wrote a comprehensive 
review on bacterial probiotics potential to prevent AMR which concluded that it is still unknown 
if probiotics could prevent the development and spread of AMR organisms. Nonetheless, it was 
hypothesized that there could be reduced persistence and evolution of AMR because probiotics 
can positively modulate gut bacteria and reduce enteric pathogens; thus, reducing the need for 
antibiotic interventions to control diarrhea. Williams et al. (2018) observed that the direct fed 
microbial (DFM) blend of Bacillus licheniformis and Bacillus subtilus or DFM blend of 
Enterococcus faecium, Lactobacillus reuteri, Lactobacillus salivarius, and Pediococcus 
acidilactici had no impact on the AMR of nursery pig fecal E.coli isolates to the same 14 
antimicrobials that were evaluated in this study. Similarly, we observed that dietary addition of 
live yeast and yeast extracts had no impact on the AMR of 14 antibiotics that are important to 
human and animal health.  
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In conclusion, adding pharmacological levels of Zn proved to be a useful additive to stimulate 
intake, increase growth, and improve fecal consistency in the early nursery period while 
optimizing feed cost per kg of gain, revenue, and IOFC. Although feeding high levels of Zn did 
tend to increase the MIC of fecal E.coli to ciprofloxacin, all fecal E.coli isolates were well under 
the CLSI (2018) resistance breakpoint. Thus, the short-term use of pharmacological levels of Zn 
did not increase antimicrobial resistance. There was no statistical response observed from the 
dietary addition of live yeast and yeast extracts for any of the growth, economic, fecal DM, or 
AMR profiles of fecal E.coli. 
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Table 1-1. Composition of phase 1, phase 2, and phase 3 diets (as-fed basis)1 
 Item Phase 1   Phase 2  Phase 3 
Ingredients, %      
   Corn 43.98  57.10  64.70 
   Soybean meal, 46.5% CP 18.10  26.35  31.30 
   Whey powder 25.00  10.00  --- 
   Fish meal  4.50  ---  --- 
   Enzymatically-treated soybean meal2 3.75  2.00  --- 
   Soybean oil 1.50  ---  --- 
   Calcium carbonate 0.30  0.90  0.85 
   Monocalcium phosphate, 21% P 0.48  1.10  1.00 
   Sodium chloride 0.30  0.55  0.60 
   L-Lys-HCl 0.43  0.51  0.52 
   DL-Met 0.22  0.22  --- 
   MHA3 ---  ---  0.25 
   L-Thr 0.18  0.21  0.22 
   L-Trp 0.07  0.06  0.06 
   L-Val 0.13  0.14  0.13 
   Vitamin premix4  0.25  0.25  --- 
   Vitamin premix with phytase5 ---  ---  0.25 
   Trace mineral premix6 0.15  0.15  0.15 
   Phytase7 0.08  0.08  --- 
   Zinc oxide8 ±  ±  --- 
   Yeast additives9 ±   ±   --- 
Total 100  100  100 




Table 1-1. (cont.)           
  Phase 1   Phase 2    Phase 3 
Calculated analysis      
SID amino acids, %     
   Lys  1.40  1.35  1.35 
   Ile:Lys 56  55  55 
   Leu:Lys 109  111  114 
   Met:Lys 38  36  36 
   Met and Cys:Lys 57  57  57 
   Thr:Lys 63  63  63 
   Trp:Lys 20.6  20.2  20.3 
   Val:Lys 69  69  69 
   His:Lys 32  34  36 
Total Lys, % 1.53  1.48  1.49 
ME, kcal/kg 3,408  3,267  3,271 
NE, kcal/kg 2,565  2,429  2,416 
SID Lys:NE, g/Mcal 5.44  5.54  5.57 
CP, % 20.9  20.5  21.2 
Ca, % 0.69  0.77  0.72 
P, % 0.68  0.66  0.61 
STTD P, % 0.63  0.58  0.50 
Zn, mg/kg 110 vs 3,000   110 vs 2,000   110 
1 Phase 1 diets were fed from d 0 to 7 (approximately 5.6 to 6.1 kg) and phase 2 diets were fed from d 7 to 
21 (approximately 6.1  to 11.6 kg). Both phases were manufactured at the Kansas State University Poultry 
Unit (Manhattan, KS). A common diet, without ZnO or yeast probiotics, was fed during phase 3 from d 21 to 
42 (approximately 11.6 to 24.0 kg). The common diet was manufactured by Hubbard Feeds (Beloit, KS).  
2 HP 300, Hamlet Protein, Findlay, OH. 
3 Methionine hydroxy analogue, Novus International, St. Charles, MO. 
4 Provided per kg of premix: 1,653,465 IU vitamin A; 661,386 IU vitamin D; 17,637 IU vitamin E; 1,322 
mg vitamin K; 13.2 mg vitamin B12; 19,841 mg niacin; 11,023 mg pantothenic acid; 3,307 mg riboflavin. 
5 Ronozyme HiPhos GT 2700 (DSM Nutritional Products, Parsippany, NJ) provided 1,250 FTU/kg and an 
expected STTD P release of 0.12%. Provided per kg of premix: 1,653,465 IU vitamin A; 661,386 IU vitamin 
D; 17,637 IU vitamin E; 1,322 mg vitamin K; 13.2 mg vitamin B12; 19,841 mg niacin; 11,023 mg pantothenic 
acid; 3,307 mg riboflavin. 
6Provided per kg of premix: 73 g Zn from Zn sulfate; 73 g Fe from iron sulfate; 22 g Mn from manganese 
oxide; 11 g Cu from copper sulfate; 0.2 g I from calcium iodate; 0.2 g Se from sodium selenite. 
7  Ronozyme HiPhos 2700 (DSM Nutritional Products, Parsippany, NJ) provided 2,027 FTU/kg and an 
estimated release of 0.14% STTD P in phases 1 and 2.  
8 ZnO was fed to supply 3,000 mg/kg of Zn for the duration of phase 1 and 2,000 mg/kg of Zn for the 
duration of phase 2.  
9 Yeast pre- & probiotics included 0.10% ActiSaf Sc 47 HR+, 0.05% SafMannan, and 0.05% NucleoSaf in 
phase 1 diets and then concentrations were lowered by 50% in phase 2 diets (Phileo by Lesaffre, Milwaukee, 
WI). 
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Table 1-2. Diet analysis (as-fed basis), %1 
  No yeast additives  Yeast additives
2  
  Low Zn High Zn   Low Zn High Zn 
Phase 1 diets      
   DM, % 91.8 91.9  91.9 91.9 
   CP, % 20.5 19.9  20.2 20.1 
   Ca, % 1.23 1.23  1.20 1.20 
   P, % 0.77 0.75  0.77 0.76 
   Zn, mg/kg 263 3,230  245 3,204 
   Live yeast, CFU/g 200 500  7,100,000 9,700,000 
Phase 2 diets      
   DM, % 90.2 90.1  89.7 89.8 
   CP, % 18.9 19.0  19.1 19.6 
   Ca, % 1.38 1.41  1.38 1.33 
   P, % 0.73 0.72  0.74 0.72 
   Zn, mg/kg 234 2,435  257 2,233 
   Live yeast, CFU/g 300 700  10,500,000 5,900,000 
Phase 3 common diet      
   DM, % 88.4 ---  --- --- 
   CP, % 20.7 ---  --- --- 
   Ca, % 0.95 ---  --- --- 
   P, % 0.61 ---  --- --- 
   Zn, mg/kg 199 ---  --- --- 
1 Complete diet samples were obtained from each treatment during manufacturing and 
homogenized to form a composite sample. Samples were submitted to Ward 
Laboratories (Kearney, NE) to analyze DM, CP, Ca, P and Zn. Phase 1 and 2 diets were 
also sent to Analabs (Fulton, IL) to analyze active live yeast. 
2 Yeast pre- & probiotics included ActiSaf SC 47 HR+ at 0.1%, SafMannan at 0.05% 
and NucleoSaf at 0.05% in phase 1 diets and then concentrations were lowered by 50% 




Table 1-3. Resistance breakpoints and evaluated concentrations for antimicrobials of National Antimicrobial Resistance Monitoring 










Amoxicillin:clavulanic acid 2:1 ratio Critically important ≤ 8/4 16/8 ≥ 32/16 
Ampicillin Critically important ≤ 8 16 ≥ 32 
Azithromycin Critically important ≤ 16 N/A3 ≥ 32 
Cefoxitin Highly important ≤ 8 16 ≥ 32 
Ceftiofur Critically important ≤  2 4 ≥ 8 
Ceftriaxone Critically important ≤ 1 2 ≥ 4 
Chloramphenicol Highly important ≤ 8 16 ≥ 32 
Ciprofloxacin Critically important ≤ 0.06 ≥ 0.12 ≥ 0.12 
Gentamicin Critically important ≤ 4 8 ≥ 16 
Nalidixic acid Critically important ≤ 16 N/A ≥ 32 
Streptomycin Critically important ≤ 16 N/A ≥ 32 
Sulfisoxazole Highly important ≤ 256 N/A ≥ 512 
Tetracycline Highly important ≤ 4 8 ≥ 16 
Trimethoprim/sulfamethoxazole 1:19 ratio Highly important ≤ 2/38 N/A ≥ 4/76 
1 Breakpoints established by Clinical and Laboratory Standards Institute (CLSI, 2018) which are categorized as susceptible (treatable), 
intermediate (possibly treatable with higher doses), and resistant (not treatable). MIC values greater than the susceptible breakpoint but lower than 
the resistant breakpoint were considered intermediate. 
2 World Health Organization (WHO) categorization of antimicrobials according to importance for human medicine (WHO, 2018). 
3 N/A = not applicable. The National Antimicrobial Resistance Monitoring System has not established breakpoints; therefore, there is no Clinical 
and Laboratory Standards Institute resistant breakpoint.  
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Table 1-4. Interactive effects of yeast pre- and probiotics and pharmacological levels of Zn on nursery pig performance1 
  No yeast additives  Yeast additives  P = 
Item Low Zn High Zn   Low Zn High Zn SEM Yeast × Zn Yeast Zn 
BW, kg          
   d 0 5.64 5.64  5.64 5.64 0.025 0.963 0.779 0.901 
   d 7 5.81 6.08  5.91 6.07 0.075 0.359 0.508 0.001 
   d 21 10.87 11.56  11.05 11.56 0.159 0.531 0.533 < 0.001 
   d 42 23.17 23.98  23.28 24.03 0.266 0.912 0.744 0.002 
Phase 1 (d 0 to 7)          
   ADG, g 25 63  39 61 9.8 0.360 0.489 0.001 
   ADFI, g 70 90  78 85 6.7 0.324 0.847 0.042 
   G:F, g/kg 190 603  404 689 94.0 0.446 0.077 < 0.001 
Phase 2 (d 7 to 21)          
   ADG, g 355 391  367 393 8.3 0.546 0.401 < 0.001 
   ADFI, g 437 492  452 492 12.3 0.538 0.507 < 0.001 
   G:F, g/kg 814 796  813 802 11.1 0.777 0.810 0.169 
Experimental period (d 0 to 21)         
   ADG, g 244 281  258 282 7.6 0.400 0.288 < 0.001 
   ADFI, g 314 356  328 356 9.8 0.456 0.461 < 0.001 
   G:F, g/kg 776 787  788 795 9.4 0.806 0.247 0.282 
Phase 3 common period (d 21 to 42)        
   ADG, g 586 591  582 594 7.8 0.685 0.947 0.264 
   ADFI, g 877 872  863 874 11.1 0.451 0.573 0.811 
   G:F, g/kg 668 679  675 680 5.5 0.619 0.502 0.158 
Overall (d 0 to 42)          
   ADG, g 413 436  420 438 6.2 0.721 0.433 0.001 
   ADFI, g 593 613  595 615 9.5 0.982 0.830 0.031 
   G:F, g/kg 697 710  706 713 5.0 0.518 0.284 0.043 
Economics, $          
   Feed cost/pig2 11.41 11.74  11.76 12.08 0.181 0.997 0.062 0.076 
   Feed cost/kg gain3 0.675 0.651  0.668 0.657 0.0079 0.345 0.923 0.014 
   Revenue4 18.76 19.91  19.45 20.29 0.355 0.631 0.100 0.003 




Fecal dry matter,%6          
   d 4 18.0 19.8  17.5 20.1 1.13 0.708 0.955 0.043 
   d 21 22.8 21.3  22.5 23.4 1.10 0.281 0.397 0.786 
   d 42 24.5 24.6   23.5 23.8 1.20 0.909 0.437 0.891 
1 A total of 360 barrows (initially 5.6 ± 0.03 kg) were used in a 42-d growth study with 5 pigs per pen and 18 pens per treatment. Yeast 
pre- & probiotics included ActiSaf Sc 47 HR+ at 0.10%, SafMannan at 0.05% and NucleoSaf at 0.05% in phase 1 diets and then 
concentrations were lowered by 50% in phase 2 diets (Phileo by Lesaffre, Milwaukee, WI).  ZnO was fed to supply 3,000 mg/kg of Zn for 
the duration of phase 1 and 2,000 mg/kg of Zn for the duration of phase 2. 
2 Feed cost per pig = total feed cost ÷ pigs placed in the pen. 
3 Feed cost per kg gain = feed cost per pig ÷ body weight gain per pig. 
4 Revenue = (gain per pig x $1.47/kg) x assumed 75% yield. 
5 Income over feed cost = revenue – feed cost per pig. 
6 Fecal samples from the same 3 pigs/pen were collected on d 4, 21, and 42. Zinc × yeast × day, P = 0.790; Zinc × day, P = 0.220; 
Yeast × day, P = 0.515. 
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Table 1-5. Main effects of yeast pre- and probiotics and pharmacological levels of Zn on nursery pig performance1  
 Yeast additives   Zinc   
Item No yeast Yeast SEM P = Low Zn High Zn SEM P = 
BW, kg         
   d 0 5.64 5.64 0.024 0.779 5.64 5.64 0.024 0.901 
   d 7 5.95 5.99 0.060 0.508 5.86 6.07 0.060 0.001 
   d 21 11.21 11.31 0.122 0.533 10.96 11.56 0.122 < 0.001 
   d 42 23.58 23.66 0.202 0.744 23.22 24.01 0.202 0.002 
Phase 1 (d 0 to 7)         
   ADG, g 44 50 7.3 0.489 32 62 7.3 0.001 
   ADFI, g 80 81 5.0 0.847 74 87 5.0 0.042 
   G:F, g/kg 397 547 73.1 0.077 297 646 73.1 < 0.001 
Phase 2 (d 7 to 21)         
   ADG, g 373 380 5.9 0.401 361 392 5.9 < 0.001 
   ADFI, g 464 472 9.0 0.507 445 492 9.0 < 0.001 
   G:F, g/kg 805 808 8.4 0.810 814 799 8.4 0.169 
Experimental period (d 0 to 21)        
   ADG, g 262 270 5.6 0.288 251 281 5.6 < 0.001 
   ADFI, g 335 342 7.3 0.461 321 356 7.3 < 0.001 
   G:F, g/kg 782 792 7.2 0.247 782 791 7.2 0.282 
Phase 3 common period (d 21 to 42)       
   ADG, g 589 588 5.8 0.947 584 593 5.8 0.264 
   ADFI, g 875 868 8.1 0.573 870 873 8.1 0.811 
   G:F, g/kg 674 677 3.9 0.502 672 680 3.9 0.158 
Overall (d 0 to 42)        
   ADG, g 424 429 4.4 0.433 417 437 4.4 0.001 
   ADFI, g 603 605 7.0 0.830 594 614 7.0 0.031 
   G:F, g/kg 704 709 3.5 0.284 702 712 3.5 0.043 
Economics, $         
   Feed cost/pig2 11.58 11.92 0.129 0.062 11.58 11.91 0.129 0.076 
   Feed cost/kg gain3 0.663 0.662 0.0062 0.923 0.671 0.654 0.0062 0.014 
   Revenue4 19.34 19.87 0.274 0.100 19.11 20.10 0.274 0.003 
   IOFC5 7.76 7.95 0.188 0.344 7.52 8.19 0.188 0.002 
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Fecal dry matter, %6         
   d 4 18.9 18.8 0.82 0.955 17.7 20.0 0.82 0.043 
   d 21 22.0 22.9 0.81 0.397 22.6 22.3 0.81 0.786 
   d 42 24.5 23.6 0.85 0.437 24.0 24.2 0.85 0.891 
1 A total of 360 barrows (initially 5.6 ± 0.03 kg) were used in a 42-d growth study with 5 pigs per pen and 36 pens per treatment. Yeast pre- 
& probiotics included ActiSaf Sc 47 HR+ at 0.10.%, SafMannan at 0.05% and NucleoSaf at 0.05% in phase 1 diets and then concentrations 
were lowered by 50% in phase 2 diets (Phileo by Lesaffre, Milwaukee, WI). ZnO was fed to supply 3,000 mg/kg of Zn for the duration of phase 
1 and 2,000 mg/kg of Zn for the duration of phase 2. 
2 Feed cost per pig = total feed cost ÷ pigs placed in the pen. 
3 Feed cost per kg gain = feed cost per pig ÷ body weight gain per pig. 
4 Revenue = (gain per pig x $1.47/kg) x assumed 75% yield. 
5 Income over feed cost = revenue – feed cost per pig. 
6 Fecal samples from the same 3 pigs/pen were collected on d 4, 21, and 42. Zinc × yeast × day, P = 0.790; Zinc × day, P = 0.220; Yeast × 





Table 1-6. Interactive effects of yeast pre- and probiotics and pharmacological levels of Zn over time on antimicrobial susceptibilities of fecal 
Escherichia coli according to National Antimicrobial Resistance Monitoring System (CLSI, 2018) established breakpoints1 
  No yeast additives  Yeast additives
3  P = 
Item Low Zn High Zn4   Low Zn High Zn  Yeast × Zn Yeast × Day Zn × Day Yeast × Zn × Day 
Amoxicillin:clavulanic acid 2:1 ratio5     0.342 0.445 0.644 0.461 
   d 4 10.5 ± 2.1 14.8 ± 2.9  10.1 ± 2.0 10.5 ± 2.1      
   d 21 11.8 ± 2.3 14.8 ± 2.9  18.0 ± 3.5 13.7 ± 2.7      
   d 42 16.0 ± 3.2 13.7 ± 2.7  14.3 ± 2.8 14.8 ± 2.9      
Ampicillin      0.625 0.720 0.480 0.757 
   d 4 18.0 ± 4.1 19.4 ± 4.4  14.8 ± 3.4 21.8 ± 5.0      
   d 21 21.0 ± 3.4 21.8 ± 3.6  25.4 ± 4.2 24.4 ± 4.0      
   d 42 32.0 ± 1.2 29.6 ± 1.1  32.0 ± 1.2 32.0 ± 1.2      
Azithromycin      0.874 0.559 0.558 0.929 
   d 4 11.3 ± 1.7 13.2 ± 2.0  10.5 ± 1.6 11.8 ± 1.8      
   d 21 6.6 ± 1.0 7.4 ± 1.1  5.9 ± 0.9 7.4 ± 1.1      
   d 42 9.3 ± 1.4 9.0 ± 1.3  10.5 ± 1.6 10.1 ± 1.5      
Cefoxitin      0.294 0.704 0.672 0.865 
   d 4 10.1 ± 1.8 13.7 ± 2.4  11.8 ± 2.1 12.2 ± 2.2      
   d 21 11.8 ± 2.1 13.7 ± 2.4  16.6 ± 2.9 14.8 ± 2.6      
   d 42 14.3 ± 2.5 18.7 ± 3.3  14.8 ± 2.6 18.7 ± 3.3      
Ceftiofur      0.807 0.670 0.658 0.970 
   d 4 2.33 ± 0.69 2.24 ± 0.66  2.00 ± 0.59 2.02 ± 0.60      
   d 21 2.52 ± 0.75 1.92 ± 0.57  3.43 ± 1.02 2.33 ± 0.69      
   d 42 2.83 ± 0.84 3.17 ± 0.94  3.43 ± 1.02 3.30 ± 0.98      
Ceftriaxone      0.307 0.763 0.572 0.794 
   d 4 1.53 ± 0.68 2.42 ± 1.08  2.33 ± 1.04 1.46 ± 0.65      
   d 21 1.85 ± 0.82 2.08 ± 0.92  3.17 ± 1.41 2.83 ± 1.26      
   d 42 6.11 ± 2.71 3.56 ± 1.58  7.13 ± 3.17 3.70 ± 1.65      
Chloramphenicol       0.999 0.189 0.952 0.828 
   d 4 21.0 ± 3.5 22.6 ± 3.7  18.0 ± 3.0 18.0 ± 3.0      
   d 21 16.0 ± 3.0 16.0 ± 3.0  21.8 ± 4.1 20.2 ± 3.8      
   d 42 24.4 ± 3.1 22.6 ± 2.9  22.6 ± 2.9 24.4 ± 3.1               
           Continued  
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Table 1-6. (cont.) 
  No yeast additives  Yeast additives
2  P = 
Item Low Zn High Zn3   Low Zn High Zn  Yeast × Zn Yeast × Day Zn × Day Yeast × Zn × Day 
Ciprofloxacin      0.566 0.714 0.542 0.877 
   d 4 0.0221 ± 0.0057 0.0313 ± 0.0081 0.0182 ± 0.0047 0.0269 ± 0.0070      
   d 21 0.0213 ± 0.0055 0.0314 ± 0.0081 0.0197 ± 0.0051 0.0447 ± 0.0116      
   d 42 0.0428 ± 0.0156 0.0462 ± 0.0169 0.0413 ± 0.0151 0.0541 ± 0.0197      
Gentamicin      0.066 0.559 0.722 0.631 
   d 4 3.30 ± 1.01 1.71 ± 0.53  2.33 ± 0.72 3.17 ± 0.98      
   d 21 4.00 ± 1.23 2.52 ± 0.77  5.66 ± 1.74 4.67 ± 1.43      
   d 42 4.16 ± 1.28 2.62 ± 0.80  2.83 ± 0.87 4.49 ± 1.38      
Nalidixic acid      0.524 0.957 0.701 0.638 
   d 4 2.72 ± 0.47 3.05 ± 0.53  2.94 ± 0.51 3.05 ± 0.53      
   d 21 2.62 ± 0.38 3.17 ± 0.46  2.52 ± 0.37 3.30 ± 0.48      
   d 42 3.56 ± 0.72 4.49 ± 0.91  4.16 ± 0.84 3.56 ± 0.72      
Streptomycin      0.932 0.771 0.415 0.582 
   d 4 47.0 ± 6.5 54.9 ± 7.6  48.9 ± 6.8 56.7 ± 7.9      
   d 21 47.0 ± 6.5 54.9 ± 7.6  52.8 ± 7.3 50.8 ± 7.0      
   d 42 54.9 ± 7.6 43.5 ± 6.0  57.0 ± 7.9 57.0 ± 7.9      
Sulfisoxazole      0.879 0.183 0.215 0.410 
   d 4 174 ± 34 246 ± 48  138 ± 27 161 ± 31      
   d 21 228 ± 31 188 ± 26  256 ± 35 211 ± 29      
   d 42 256 ± 21 219 ± 18  228 ± 19 256 ± 21      
Trimethoprim/sulfamethoxazole 1:19 ratio 4     0.366 0.904 0.902 0.259 
   d 4 0.179 ± 0.037 0.236 ± 0.049  0.193 ± 0.040 0.178 ± 0.037      
   d 21 0.146 ± 0.025 0.152 ± 0.026  0.125 ± 0.021 0.185 ± 0.032     
   d 42 0.377 ± 0.131 0.696 ± 0.242  0.555 ± 0.193 0.474 ± 0.165           
1 A total of 360 barrows (initial BW of 5.6 ± 0.03 kg) were used in a 42-d study with 5 pigs per pen and 18 pens per treatment. Fecal samples from the 
same 3 pigs/pen were collected on d 4, 21, and 42  for E.coli isolation and further characterization. Data reported as geometric mean of MIC ± SEM. 
2 Yeast pre- & probiotics included ActiSaf Sc 47 HR+ at 0.10%, SafMannan at 0.05% and NucleoSaf at 0.05% in phase 1 diets and then 
concentrations were lowered by 50% in phase 2 diets (Phileo by Lesaffre, Milwaukee, WI).   
3 ZnO was fed to supply 3,000 mg/kg of Zn for the duration of phase 1 and 2,000 mg/kg of Zn for the duration of phase 2.  
4 The MIC numerator of the ratio was reporter for the antimicrobial’s amoxicillin:clavulanic acid and trimethoprim/sulfamethoxazole. 
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Table 1-7. Main effects of yeast pre- and probiotics, pharmacological levels of Zn, and day of sampling on antimicrobial susceptibilities of fecal Escherichia coli 
according to National Antimicrobial Resistance Monitoring System (CLSI, 2018) established breakpoints1 
 Yeast additives
2  Zn
3  Day  
Item No yeast Yeast P = Low Zn High Zn P = 4 21 42 P = 
Amoxicillin:clavulanic 
acid 2:1 ratio5 
13.5 ± 1.0 13.3 ± 1.0 0.905 13.1 ± 1.0 13.6 ± 1.0 0.721 11.3 ± 1.1 14.4 ± 1.4 14.7 ± 1.4 0.134 
Ampicillin 23.1 ± 1.7 24.3 ± 1.8 0.625 22.9 ± 1.7 24.4 ± 1.8 0.541 18.3 ± 2.1a 23.1 ± 1.9a 31.4 ± 0.6b < 0.001 
Azithromycin 9.21 ± 0.64 9.10 ± 0.63 0.876 8.75 ± 0.60 9.58 ± 0.66 0.272 11.65 ± 0.96b 6.79 ± 0.56a 9.70 ± 0.80b < 0.001 
Cefoxitin 13.5 ± 1.0 14.6 ± 1.1 0.367 13.0 ± 1.0 15.1 ± 1.1 0.112 11.9 ± 1.1a 14.1 ± 1.3ab 16.5 ± 1.6b 0.030 
Ceftiofur 2.47 ± 0.30 2.67 ± 0.32 0.606 2.70 ± 0.32 2.44 ± 0.29 0.505 2.14 ± 0.33 2.50 ± 0.39 3.17 ± 0.49 0.189 
Ceftriaxone 2.60 ± 0.49 3.05 ± 0.58 0.443 3.11 ± 0.59 2.55 ± 0.48 0.336 1.88 ± 0.46a 2.42 ± 0.60a 4.90 ± 1.20b 0.011 
Chloramphenicol 20.2 ± 1.3 20.7 ± 1.3 0.774 20.4 ± 1.3 20.4 ± 1.3 0.999 19.8 ± 1.6ab 18.3 ± 1.7a 23.5 ± 1.5b 0.087 








Gentamicin 2.92 ± 0.43 3.68 ± 0.54 0.232 3.56 ± 0.52 3.02 ± 0.44 0.386 2.54 ± 0.41a 4.04 ± 0.65b 3.43 ± 0.55ab 0.072 
Nalidixic acid 3.22 ± 0.23 3.22 ± 0.23 1.000 3.04 ± 0.21 3.41 ± 0.24 0.253 2.94 ± 0.25a 2.88 ± 0.21a 3.92 ± 0.40b 0.029 
Streptomycin 50.1 ± 2.8 53.8 ± 3.0 0.288 51.1 ± 2.9 52.7 ± 3.0 0.633 51.7 ± 3.9 51.3 ± 3.8 52.8 ± 4.0 0.958 




0.250 ± 0.025 0.244 ± 0.025 0.848 0.226 ± 0.023 0.270 ± 0.027 0.210 0.195 ± 0.020b 0.151 ± 0.013a 0.512 ± 0.089c < 0.001 
1 A total of 360 barrows (initial BW of 5.6 ± 0.03 kg) were used in a 42-d study with 5 pigs per pen and 36 pens per treatment. Fecal samples from the same 3 
pigs/pen were collected on d 4, 21, and 42 for E.coli isolation and further characterization. Data reported as geometric mean of MIC ± SEM. 
2 Yeast pre- & probiotics included ActiSaf Sc 47 HR+ at 0.1%, SafMannan at 0.05% and NucleoSaf at 0.05% in phase 1 diets and then concentrations were lowered 
by 50% in phase 2 diets (Phileo by Lesaffre, Milwaukee, WI).   
3 ZnO was fed to supply 3,000 mg/kg of Zn for the duration of phase 1 and 2,000 mg/kg of Zn for the duration of phase 2.  
4 The MIC numerator of the ratio was reporter for the antimicrobial’s amoxicillin:clavulanic acid and trimethoprim/sulfamethoxazole. 
a,b,c Superscripts signify a statistical difference of P < 0.05. 
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CHAPTER 2- The effect of live yeast and yeast extracts included in 1 
lactation diets on sow and litter performance and antimicrobial 2 
susceptibility of fecal Escherichia coli: I Sow performance 3 
 4 
 Abstract 5 
A total of 80 sows (Line 241; DNA Genetics) across three farrowing groups were used in 6 
a study to evaluate the effect of feeding live yeast and yeast extracts to lactating sows on sow and 7 
litter performance and antimicrobial resistance (AMR) patterns of sow fecal E.coli. Sows were 8 
blocked by farrowing group, BW, and parity on d 110 of gestation and allotted to 1 of 2 dietary 9 
treatments. Dietary treatments consisted of a standard lactation diet or a diet that contained yeast-10 
based pre- and probiotics (0.10% Actisaf Sc 47 HR+ and 0.025% SafMannan; Phileo by 11 
Lesaffre, Milwaukee, WI). Diets were fed from d 110 of gestation until weaning (approximately 12 
d 19 post-farrow). A tendency (P = 0.073) was observed for increased feed intake through 13 
lactation when sows were fed a diet with yeast additives compared to the control diet. There was 14 
no evidence (P > 0.10) that treatment influenced any other sow or litter performance criteria. 15 
Fecal samples were collected from the first farrowing group (27 sows) to determine the AMR 16 
patterns of E.coli upon entry into the farrowing house and at weaning. E.coli was isolated from 17 
fecal samples and species confirmation was by PCR detection of uidA and clpB genes. 18 
Microbroth dilution method was used to determine the minimal inhibitory concentrations (MIC) 19 
of E.coli isolates to 14 different antimicrobials. Isolates were categorized as either susceptible, 20 
intermediate, or resistant based on Clinical and Laboratory Standards Institute guidelines. An 21 
interaction (P = 0.026) of diet × sampling day was observed for cefoxitin where fecal E.coli 22 
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showed no evidence of treatment differences (P = 0.237) in MIC values at entry, but sows fed 23 
the control diet had lower (P = 0.035) MIC values at weaning compared to sows fed yeast 24 
additives. There were no diet main effects (P > 0.10) on the AMR of fecal E.coli. There was an 25 
increased (P < 0.02) trend towards resistance for 11 of the 14 antimicrobials over time. Fecal 26 
E.coli were resistant to tetracycline and ceftriaxone at weaning. Fecal E.coli were considered 27 
susceptible or intermediate across sampling day to the remaining antimicrobials. In conclusion, 28 
feeding live yeast and yeast extracts tended to increase feed intake during lactation but did not 29 
influence either sow or litter performance measurements or the AMR of fecal E.coli during 30 
lactation except for cefoxitin which had a higher MIC at the end of lactation when yeast 31 
additives were present in the diet. 32 
 33 
Key Words: Antimicrobial resistance, sows, litter performance, live yeast, yeast extract 34 
 35 
 36 
 Abbreviations 37 
ADFI: Average daily feed intake 38 
ADG: Average daily gain 39 
AMR: Antimicrobial resistance 40 
ATCC: American Type Culture Collection 41 
BF: Back fat 42 
BW: Body weight   43 
CFU: Colony-forming unit 44 
CLSI: Clinical and Laboratory Standards Institute 45 
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CP: Crude protein 46 
MIC: Minimal inhibitory concentration  47 
NARMS: National Antimicrobial Resistance Monitoring System 48 
NE: Net energy  49 
NRC: National Research Council 50 
PCR: Polymerase chain reaction 51 
PWM: Preweaning mortality  52 
SEM: Standard error of the mean 53 
SID: Standardized ileal digestible 54 
STTD: Standardized total tract digestible 55 
WEI: Wean-to-estrus interval 56 




Supplementing live yeast and yeast extracts in sow diets has been researched due to 
potential for a healthier/heavier piglet, which may be better equipped to handle weaning stress 
leading to improved nursery performance. The inclusion of live yeast has positively influenced 
IgG in sow plasma and colostrum allowing increased maternal transfer of immunity to their 
offspring (Zanello et al., 2012; Peng et al., 2020). Furthermore, feeding live yeast and yeast 
extracts may positively modulate sow gut microflora, which may provide piglets with exposure 
to more beneficial and less pathogenic bacteria through the sow’s feces (Hasan et al., 2018). 
Additionally, feeding Saccharomyces cerevisiae through gestation and lactation has shown to 
improve average daily gain (ADG), increase body weight (BW), and improve gross energy 
digestibility of offspring in the nursery (Lu et al., 2019).  
While there are many studies exploring the effects of feeding live yeast to sows and its 
influence on litter performance in the farrowing house, there is little-to-no data related to the 
impacts of feeding live yeast and yeast extracts on the antimicrobial resistance (AMR) of gut 
bacteria in sows. Thus, the objective of this study was to evaluate the effects of feeding the live 
yeast Saccharomyces cerevisiae strain NCYC Sc 47 and a yeast cell wall fraction with 
concentrated mannan-oligosaccharides and β-glucans from S. cerevisiae on sow and litter 
performance and antimicrobial susceptibility of E.coli isolated from the feces of sows. Our 
hypothesis was that supplementing live yeast and yeast extracts to sows would lessen the AMR 
of fecal E.coli to antimicrobials that are important to human and animal medicine and may have 





 Materials and Methods 
 Animals and treatment structure 
The Kansas State University Institutional Care and Use Committee approved the protocol 
used in this experiment. A total of 80 mixed-parity sows (DNA 241, DNA Genetics) were used 
across three batch farrowing groups with 40 sows per treatment at the Kansas State University 
Swine Teaching and Research Center in Manhattan, KS. On d 110 of gestation, sows were 
weighed and moved into the farrowing house. Sows were blocked by farrowing group, parity, 
and BW and allotted to one of two dietary treatments. Dietary treatments consisted of a standard 
corn-soybean meal-based lactation diet or a diet that contained yeast-based pre- and probiotics 
(0.10% Actisaf Sc 47 HR+ and 0.025% SafMannan; Phileo by Lesaffre, Milwaukee, WI). The 
live yeast S. cerevisiae strain NCYC Sc 47 (ActiSaf Sc 47 HR+) served as the yeast-based 
probiotic. The yeast-based prebiotic included a yeast cell wall fraction with concentrated 
mannan-oligosaccharides and β-glucans from S. cerevisiae (SafMannan). Both diets were 
formulated to meet or exceed National Research Council (NRC, 2012) requirement estimates 
(Table 2-1).  
From d 110 until farrowing (approximately d 115), sows were fed approximately 2.7 kg 
of their respective treatment diets. Post farrowing, sows were allowed ad libitum access to feed 
during lactation which was recorded by weighing the amount of feed placed in the feeder and the 
amount remaining at weaning. The diets for the first farrowing group were manufactured at the 
Kansas State University O.H. Kruse Feed Technology Innovation Center (Manhattan, KS) and 
the diets for the following two farrowing groups were manufactured at a commercial feed mill 
(Hubbard Feeds; Beloit, KS).  
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Sow BW was measured at entry into the farrowing house, 24 h after farrowing, and at 
weaning. Sow back fat (BF) depth (measured 7 cm from the midline at the last rib) was measured 
at entry to the farrowing house and at weaning. Cross-fostering of piglets was performed to 
equalize litter size within sow treatment group within 48 h after birth. Litters were weighed on d 2, 
10, and at weaning. Pre-weaning mortality was calculated as the total mortality (d 0 to wean) per sow 
divided by the total born alive per sow with cross-fostered pigs accounted for in the calculations.   
 
 Chemical analysis 
Complete diet samples were taken from every fifth 23 kg bag using a feed probe. 
Complete diet samples were stored at -20C until they were homogenized, subsampled, and 
submitted for quantification (Analabs; Fulton, IL; method 997.02; AOAC International, 1998) of 
active live yeast (Table 2-1). 
 
 Fecal collection  
Fecal samples were collected from the first farrowing group (27 sows) to determine the 
antimicrobial resistance patterns of E.coli upon entry into the farrowing house and at weaning. Fecal 
samples were collected directly from the rectum of each sow using a sterile, single-use cotton 
tipped applicator (Fisher Healthcare, Pittsburgh, PA) from 13 or 14 sows per treatment. Samples 
were stored in a clean, single-use zipper storage bag and kept on ice until delivered to the Kansas 







 E.coli isolation 
Approximately 1 g of fecal sample was suspended in 9 mL of phosphate-buffered saline. 
Fifty microliters of the fecal suspension were then spread-plated onto a MacConkey agar (Becton 
Dickinson, Sparks, MD) for the isolation of E.coli. Two lactose-fermenting colonies were picked 
from each MacConkey agar and then individually streaked onto a blood agar plate (Remel, 
Lenexa, KS) and incubated at 37°C for 24 h. Indole test was done and indole-positive isolates 
were stored in cryo-protect beads (Cryocare, Key Scientific Products, Round Rock, TX) at 
−80°C. Species confirmation of E.coli was accomplished by polymerase chain reaction (PCR) 
for uidA and clpB genes. 
 
 Antimicrobial susceptibility testing of E.coli isolates 
Antimicrobial susceptibility testing was accomplished on one E.coli isolate per fecal 
sample recovered when sows entered the farrowing house (approximately d 110 of gestation) and 
at weaning (approximately 19 d post-farrowing). The microbroth dilution method as outlined by 
the Clinical and Laboratory Standards Institute (CLSI, 2018) was used to determine the minimal 
inhibitory concentrations (MIC) of several antibiotics. The antimicrobials evaluated included: 
amoxicillin/clavulanic acid 2:1 ratio, ampicillin, azithromycin, cefoxitin, ceftiofur, ceftriaxone, 
chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfisoxazole, 
tetracycline, and trimethoprim/sulfamethoxazole. Each isolate, stored in cryo-protect beads, was 
streaked onto a blood agar plate and incubated at 37°C for 24 h. Individual colonies were 
suspended in demineralized water (Trek Diagnostic Systems, Cleveland, OH) and turbidity was 
adjusted to 0.5 McFarland turbidity standards. Then, 10 µL of the bacterial inoculum was added 
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to Mueller–Hinton broth and vortexed to mix. A Sensititre automated inoculation delivery 
system (Trek Diagnostics Systems) was used to dispense 100 µL of the culture into National 
Antimicrobial Resistance Monitoring System (NARMS) panel plates designed for Gram-
negative (CMV3AGNF, Trek Diagnostic Systems) bacteria. Escherichia coli ATCC 25922 
(American Type Culture Collection, Manassas, VA) strains were included as quality controls for 
E.coli susceptibility testing. Plates were incubated at 37°C for 18 h and bacterial growth was 
assessed using Sensititre ARIS and Vizion systems (Trek Diagnostic Systems). Clinical and 
Laboratory Standards Institute (CLSI, 2018; Table 1-3) guidelines were used to classify each 
isolate as susceptible, intermediate, or resistant according to the breakpoints established for each 
antimicrobial. MIC values greater than the susceptible breakpoint but lower than the resistant 
breakpoint were considered intermediate.  
 
 Statistical analysis  
Sow and litter performance. Performance data were analyzed using the lme4 package of 
R (Version 4.0.0, R Foundation for Statistical Computing, Vienna, Austria) as a randomized 
complete block design. Blocking structure accounted for group, parity, and BW. For all analyses, 
sow was considered the experimental unit. Treatment was included as a fixed effect with block 
included as a random effect. Performance related to bodyweight, lactation length, and body fat 
was modeled by normal distribution with identity link. Count of total born, litter size, and parity 
were modeled by both Poisson and negative binomial distributions with log link and model fit 
was superior using the negative binomial response distribution through evaluation of the 
Bayesian Information Criterion. Proportion of piglets within each litter born alive, stillborn, or 
mummified, and pre-weaning mortality was modeled by a binomial distribution with logit link. 
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Differences between treatments were considered significant at P ≤ 0.05 and marginally 
significant at 0.05 < P ≤ 0.10. 
Antimicrobial susceptibility. The MIC data of each antimicrobial were analyzed using a 
linear mixed model. Fixed effects of the model included diet, sampling day, and their interaction. 
Random effects included block and sow (i.e., the error term vector corresponding to repeated 
measurement over sampling day). The variance-covariance structure of sow was taken as either 
compound symmetry or unstructured according to the model fitting criteria. To better satisfy model 
assumptions, data underwent natural log transformation before statistical modeling. Treatment 
effect was assessed via back-transformed least squares means, i.e., geometric means. Comparisons 
were carried out using the 2-sided test. Statistical analysis was performed using Statistical Analysis 
Software (SAS version 9.4; Cary, NC) PROC MIXED with option DDFM=KR in the MODEL 
statement. Differences between treatments were considered significant at P ≤ 0.05. 
 
 Results 
 Sow & litter performance  
Inclusion of yeast additives from d 110 of gestation through weaning resulted in no 
statistical difference (P > 0.10) for sow BW or BW change throughout lactation (Table 2-2). 
Furthermore, there was no evidence of treatment differences (P > 0.10) for sow BF at entry or 
weaning, or the loss in BF from entry to weaning. There was a tendency (P = 0.073) for 
increased feed intake from farrowing to weaning when sows were fed the diet with yeast 
additives compared to the control diet. There was no evidence of treatment difference (P > 0.10) 
in wean-to-estrus interval (WEI).  
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There was no evidence (P > 0.10; Table 2-3) that the addition of a live yeast and a yeast 
extract in sow diets influenced litter characteristics including litter size, litter weight, or mean 
piglet BW on d 2 post-farrowing, d 10 post-farrowing, or at weaning. Furthermore, the addition 
of yeast additives showed no evidence of a difference (P > 0.10) on litter or piglet ADG, or 
preweaning mortality (PWM).  
 
 Antimicrobial resistance  
An interaction (P = 0.026) of diet × sampling day was observed for AMR for the 
antimicrobial cefoxitin (Table 2-4). It was observed that fecal E.coli isolates from sows fed the 
control diet had lower (P = 0.035) MIC values at weaning compared to sows fed the diet with 
added yeast-based pre- and probiotics. However, there was no significant (P > 0.10) difference in 
MIC values for cefoxitin between the two dietary treatments at entry into the farrowing house. 
There were no further interactions observed (P > 0.10). There was no evidence (P > 0.10) that 
the dietary inclusion of yeast additives influenced the AMR of fecal E.coli isolates compared to 
the control diet for any of the 14 antimicrobials evaluated (Table 2-5). 
Fecal E.coli isolates from sows fed either dietary treatment were mostly resistant to 
tetracycline. Based on CLSI (2018) guidelines, the MIC of E.coli isolates were considered 
intermediate to tetracycline from fecal samples collected at entry into the farrowing house; 
however, MIC values increased (P < 0.001) by weaning with isolates being classified as resistant 
(Resistant isolates: 14/14 for the control diet; 11/13 for the yeast diet). Interestingly, this effect 
carried over into the nursery (Chance et al., 2021c). All nursery pig fecal E.coli isolates had 
higher (P < 0.001) MIC values to tetracycline on d 5 post-weaning which then decreased on d 24 
and then slightly increased on d 45 in the nursery. Fecal E.coli was susceptible to ceftriaxone at 
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entry into the farrowing house but resistant at weaning. The remaining 12 antimicrobials were 
considered susceptible or intermediate for both treatments across both sampling days. 
E.coli isolated from sow feces had increased (P < 0.02) MIC values for 
amoxicillin/clavulanic acid, ampicillin, azithromycin, cefoxitin, ceftiofur, ceftriaxone, 
ciprofloxacin, nalidixic acid, streptomycin, tetracycline, and trimethoprim/sulfamethoxazole at 
weaning compared to when sows entered the farrowing house. In fact, fecal E.coli isolates were 
susceptible to amoxicillin/clavulanic acid, ampicillin, cefoxitin, ceftiofur, ceftriaxone, and 
streptomycin upon entry into the farrowing house but showed trends towards resistance over 
time at weaning. Whereas fecal E.coli isolates were susceptible at both time points for 
azithromycin, ciprofloxacin, nalidixic acid, streptomycin, and trimethoprim/sulfamethoxazole. 
Thus, the only antimicrobials that fecal E.coli’s MIC values did not significantly (P > 0.10) 
change over time and were considered susceptible at both time points were for chloramphenicol, 
gentamicin, and sulfisoxazole. 
 
 Discussion 
Genetic selection of highly prolific sows and shortened lactation periods has led to pigs 
entering the nursery at a lighter BW. Lower entry BW has often been associated with 
underdeveloped gastrointestinal tracts and immune systems leading to a lag in performance and 
chances of enteric infections (Moeser et al., 2017). Thus, feeding strategies to increase litter 
weight have been sought out in order to wean a heavier pig who is more physiologically 
equipped to handle the stress of weaning. Feeding sows live yeast (probiotic) and yeast extracts 
(prebiotic) has been shown to increase immunity and growth of progeny (Shen et al., 2011; Gao 
et al., 2021). We evaluated the live S. cerevisiae strain NCYC Sc 47 (ActiSaf HR+; Phileo by 
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Lesaffre, Milwaukee, WI) as the yeast-based probiotic and a yeast cell wall fraction with 
concentrated mannan-oligosaccharides and β-glucans derived from S. cerevisiae (SafMannan; 
Phileo by Lesaffre, Milwaukee, WI) as a yeast-based prebiotic in the present study. Probiotics 
are live microorganisms which are designed to withstand the harsh environment of the stomach 
and can flourish in the gastrointestinal tract while outcompeting enteric pathogens (Cameron and 
McAllister, 2019). While prebiotics have similar modes of action as probiotics, they differ in the 
sense that prebiotics are not live microbes. Instead, prebiotics are a food source that can 
selectively stimulate beneficial gut microorganisms (Menegat et al., 2019b).  
 In this study we observed that feeding live yeast and a yeast extract tended to increase 
feed intake during the lactation period. This response is similar to a recent study by Tan et al. 
(2021) which reported an increase in feed intake in the first week of lactation as the inclusion of 
a yeast extract increased from 0 to 10 g/kg in the diet from d 90 of gestation through lactation. 
However, many studies that evaluate the inclusion of yeast additives in sow diets report no 
statistical impact on sow feed intake during lactation (Kim et al., 2010; Chen et al., 2020; Gao et 
al., 2021). Unlike Tan et al. (2021), there was no evidence of treatment difference in sow BW or 
BW change in the present study. There were no evidence of treatment differences in sow BF 
thickness or change in BF thickness in studies by Shen et al. (2011), Zanello et al. (2012), and 
Peng et al. (2020) which is consistent with our observations. Interestingly, Jang et al. (2012) 
reported reduced WEI and increased percentage of estrus detection by d 7 post-weaning as the 
inclusion of live yeast and length of feeding live yeast increased. Similarly, Kim et al. (2008) 
found it required 2 d less for successful breeding post-weaning when sows were supplemented 
with the live yeast S. cerevisiae from d 35 of gestation through lactation compared to sows fed a 
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control diet. This differs from the present study as no impact on subsequent reproductive criteria 
was observed.  
 Feeding yeast and yeast extracts to sows has previously been reported to affect the sow’s 
offspring. Unlike many studies, the inclusion of live yeast and a yeast extract did not impact any 
litter performance parameters in the present study. A number of studies have reported improved 
litter weight gain and heavier weaning weights when yeast additives were fed to their dam (Kim 
et al., 2008; Shen et al., 2011; Hasan et al., 2018). In many studies, sows did not have increased 
feed intake; thus, the improvement in litter performance may be attributed to yeast’s impact on 
colostrum quality and yield (Peng et al., 2020), maternal transfer of immunity (Zanello et al., 
2012; Gao et al., 2021), increased exposure to a more diverse fecal microflora (Trckova et al., 
2014; Hasan et al., 2018), and/or improved nutrient digestibility (Lu et al., 2019). Some studies 
have reported increased total born alive (Mariella et al., 2009; Chen et al., 2020 ) and reduced 
stillborns (Peng et al., 2020), mummies (Zanello et al., 2012), and PWM (Mariella et al., 2009) 
when sows were supplemented with yeast additives, but this was not observed in our study. 
However, these studies report feeding yeast for a longer duration during gestation than the 
present study which could be a potential reason we did not observe a response for the respective 
litter characteristics.  
 There is limited data regarding the AMR of gut bacteria in swine when fed antibiotic 
alternatives. To our knowledge, this is one of the few studies reporting the AMR of fecal E.coli 
in sows when fed a diet containing yeast-based pre- and probiotics. Ouwehand et al. (2016) 
speculated that positively modulating gut bacteria through probiotic supplementation may reduce 
the need for antibiotics; thus, reducing the chances of further contribution to AMR. Yet, in 
chapter 1 we observed no statistical impact on the AMR of fecal E.coli when nursery pig diets 
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were supplemented with live yeast and yeast extracts (Chance et al., 2021a). In the present study, 
an interaction revealed increased AMR to cefoxitin over time when sows were fed yeast 
additives. However, when MIC values were averaged across the two sampling timepoints, the 
inclusion of yeast did not impact the AMR of sow fecal E.coli for any of the antibiotics tested. 
Although no antibiotics were administered during lactation, MIC values to 11 of the 14 
antimicrobials tested increased over time regardless of dietary treatment. Literature reports 
evidence that the resistance of E.coli and other gut microbes in sows can be passed down to 
progeny (Mathew et al., 2005; Stannarius et al., 2009; Callens et al., 2014). We observed that 
sows developed resistance to tetracycline during lactation, passing off the resistance to their 
offspring in the nursery which then decreased over time (Chance et al., 2021c). Our findings 
agree with other cross-sectional studies on AMR where high AMR gene levels reported among 
young pigs were attributed to sow population. This is possibly due to either vertical or horizontal 
transmission of resistance of bacteria at, or shortly after, birth and similarities in microbiome 
abundance in diversity (Sekirov et al., 2010; Marchant and Moreno, 2013; Lanza et al., 2015). 
However, more research is warranted to fully comprehend the impacts of live yeast and yeast 
extract’s impact on sow fecal AMR and its subsequent impact on the AMR of gut bacteria in 
progeny.    
In conclusion, feeding live yeast and yeast extracts from d 110 of gestation through 
lactation tended to increase lactation feed intake but did not affect any other sow or litter 
performance criteria. Furthermore, yeast additives had minimal effect on the antimicrobial 
resistance of fecal E.coli except for cefoxitin which had higher MIC values at the end of lactation 
when the live yeast and yeast extracts were present in the diet. Regardless of the diet, 11 of the 
14 antimicrobials had increased MIC values at weaning compared to entry into the farrowing 
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house with most classified as susceptible upon entry but classified as intermediate or resistant at 




Table 2-1. Composition of lactation diets (as-fed basis)1 
Ingredients, %  
   Corn 64.4 
   Soybean meal, 46.5% CP 30.0 
   Oil 2.00 
   Monocalcium P, 21% P 1.15 
   Calcium carbonate 0.90 
   Salt 0.50 
   L-Lys-HCl 0.20 
   DL-Met 0.05 
   L-Thr 0.07 
   L-Trp 0.01 
   Vitamin premix without phytase2 0.25 
   Sow vitamin pack3 0.25 
   Trace mineral premix4 0.15 
   Phytase5 0.08 
  Yeast additives6   ± 
Total 100 
  
Calculated analysis  
SID amino acids, %  
   Lys  1.07 
   Ile:Lys 67 
   Leu:Lys 140 
   Met:Lys 30 
   Met and Cys:Lys 56 
   Thr:Lys 63 
   Trp:Lys 20.7 
   Val:Lys 73 
   His:Lys 44 
Total Lys, % 1.21 
NE, kcal/kg 2,508 
SID Lys:NE, g/Mcal 4.25 
CP, % 19.9 
Ca, % 0.77 
P, % 0.63 
STTD P, % 0.50 
Live yeast, CFU/g7  76,133 or 14,866,666 
1 Feed was manufactured at the O.H. Kruse Feed Technology Innovation Center (Manhattan, KS) for the 
first farrowing group and then feed was manufactured by a commercial feed mill (Hubbard Feeds; Beloit, KS).  
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2 Provided per kg of premix: 1,653,465 IU vitamin A; 661,386 IU vitamin D; 17,637 IU vitamin E; 1,322 
mg vitamin K; 13.2 mg vitamin B12; 19,841 mg niacin; 11,023 mg pantothenic acid; 3,307 mg riboflavin. 
3 Provided per kg of premix: 1,653,465 IU vitamin A; 4,409 IU vitamin E; 88 mg biotin; 882 mg folic acid; 
397 mg pyridoxine; 220,462 mg choline; 19,842 mg carnitine; 79 mg chromium.  
4 Provided per kg of premix: 73 g Zn from Zn sulfate; 73 g Fe from iron sulfate; 22 g Mn from manganese 
oxide; 11 g Cu from copper sulfate; 0.2 g I from calcium iodate; 0.2 g Se from sodium selenite. 
5 Ronozyme HiPhos 2700 (DSM Nutritional Products, Parsippany, NJ) provided 2,027 FTU/kg and a STTD 
P release of 0.12%.  
6 Live yeast was provided by 0.10% Actisaf Sc 47 HR+ and yeast extracts were provided by 0.025% 
SafMannan (Phileo by Lesaffre, Milwaukee, WI) at the expense of corn.  
7 Average quantification between feed samples taken from the three farrowing groups. The control diet had 





Table 2-2. Effects of including live yeast and a yeast extract in lactation diets on sow performance1 
Item Control Yeast2 SEM P = 
Count, n 40 40 --- --- 
Parity 2.2 2.2 0.24 0.999 
Lactation length, d 18.7 18.7 0.15 0.603 
Sow BW, kg     
Entry 245.0 245.0 5.00 0.978 
Farrow 223.7 224.0 4.95 0.920 
Wean 217.5 218.9 5.11 0.694 
Sow BW change, kg     
Entry to farrow -21.2 -21.1 1.46 0.974 
Farrow to wean -6.1 -5.3 1.42 0.663 
Entry to wean -27.3 -26.4 2.07 0.750 
Sow back fat, mm     
Entry 12.7 12.5 0.35 0.684 
Wean 10.1 10.3 0.35 0.705 
Change (entry to wean) -2.6 -2.2 0.24 0.197 
Sow ADFI, kg     
Farrow to wean 5.65 5.90 0.121 0.073 
Wean-estrus interval, d  4.4 4.3 0.14 0.748 
1  A total of 80 mixed-parity sows (DNA 241, DNA Genetics) and litters were used in a lactation study 
from d 110 of gestation until weaning with 40 sows and litters per treatment. Litters were cross-fostered to 
equalize litter size up to 48-h post-farrowing within treatment group. 
2 Live yeast was provided by 0.10% Actisaf Sc 47 HR+ and yeast extracts were provided by 0.025% 




Table 2-3. Effects of including live yeast and a yeast extract in lactation diets on litter 
performance1 
Item Control Yeast2 SEM P = 
Litter characteristics     
Total born, n 16.2  16.6  0.65 0.639 
Born alive, % 91.4  91.1  4.50 0.960 
Stillborn, % 7.0  5.4  4.04 0.764 
Mummy, % 1.5  3.5  2.90 0.575 
Litter size, n     
d 2 14.2  14.3  0.60 0.836 
d 10 13.3  13.9  0.59 0.448 
Wean 12.9  13.5  0.58 0.498 
Litter weight, kg     
d 2 23.23 23.42 0.530 0.797 
d 10 46.33 46.19 1.739 0.946 
Wean 71.35 72.67 1.961 0.635 
Mean piglet BW, kg     
d 2  1.65 1.64 0.033 0.849 
d 10 3.48 3.34 0.118 0.312 
Wean 5.51 5.41 0.119 0.579 
Litter ADG d 2 to wean, kg/day 2.59 2.64 0.973 0.741 
Piglet ADG d 2 to wean, g/day 198 196 6.2 0.786 
Preweaning mortality, % 10.7 9.6 4.88 0.873 
Wean age 18.7 18.7 0.15 0.603 
1 A total of 80 mixed-parity sows (DNA 241, DNA Genetics) and litters were used in a lactation 
study from d 110 of gestation until weaning with 40 sows and litters per treatment. Litters were cross-
fostered to equalize litter size up to 48-h post-farrowing within treatment group. 
2 Live yeast was provided by 0.10% Actisaf Sc 47 HR+ and yeast extracts were provided by 0.025% 




Table 2-4. Interactive effects of including live yeast and a yeast extract in lactation diets over time on 
antimicrobial susceptibilities of fecal Escherichia coli in sows according to National Antimicrobial Resistance 
Monitoring System (CLSI, 2018) established breakpoints1 
   P =  
Item Control  Yeast2  Diet  Day  Diet × Day  
Amoxicillin:clavulanic acid 2:1 ratio3 0.854 < 0.001 0.876 
   Entry 4.0 ± 0.55 4.0 ± 0.55    
   Wean 19.5 ± 4.32 20.8 ± 4.79    
Ampicillin  0.276 < 0.001 0.946 
   Entry 3.8 ± 0.75 3.0 ± 0.59    
   Wean 27.6 ± 5.45 22.1 ± 4.54    
Azithromycin  0.318 0.016 0.966 
   Entry 4.6 ± 0.66 5.1 ± 0.73    
   Wean 6.6 ± 0.93 7.3 ± 1.08    
Cefoxitin4  0.186 < 0.001 0.026 
   Entry 7.6 ± 0.88 6.3 ± 0.72    
   Wean 16.0 ± 2.88 28.6 ± 5.36    
Ceftiofur  0.822 < 0.001 0.225 
   Entry 0.50 ± 0.090 0.41 ± 0.074    
   Wean 4.64 ± 0.836 6.12 ± 1.147    
Ceftriaxone  0.919 < 0.001 0.275 
   Entry 0.35 ± 0.087 0.25 ± 0.061    
   Wean 7.61 ± 3.315 11.62 ± 5.269    
Chloramphenicol   0.338 0.742 0.468 
   Entry 8.8 ± 0.95 8.8 ± 0.95    
   Wean 8.4 ± 0.90 10.1 ± 1.12    
Ciprofloxacin  0.491 0.002 0.974 
   Entry 0.017 ± 0.0015 0.020 ± 0.0018    
   Wean 0.043 ± 0.0143 0.051 ± 0.0175    
Gentamicin  0.774 0.268 0.276 
   Entry 1.05 ± 0.106 0.95 ± 0.096    
   Wean 0.91 ± 0.072 0.95 ± 0.078    
Nalidixic acid  0.369 0.009 0.859 
   Entry 2.1 ± 0.27 2.8 ± 0.36    
   Wean 4.4 ± 1.51 5.4 ± 1.93    
Streptomycin  0.657 0.017 0.345 
   Entry 10.8 ± 2.3 14.5 ± 3.1    
   Wean 23.8 ± 5.1 20.7 ± 4.6    
Sulfisoxazole  0.912 0.345 0.910 
   Entry 172 ± 44 164 ± 42    
   Wean 210 ± 36 211 ± 38    
Tetracycline  0.618 < 0.001 0.055 
   Entry 8.4 ± 2.3 14.5 ± 4.0    
   Wean 32.0 ± 4.6 23.3 ± 3.5    
Trimethoprim/sulfamethoxazole 1:19 ratio 3 0.366 0.010 0.949 
   Entry 0.12 ± 0.021 0.15 ± 0.027    
   Wean 0.30 ± 0.119 0.40 ± 0.165       
1 A total of 27 mixed-parity sows (DNA 241, DNA Genetics) and litters were used in a lactation study from d 110 of 
gestation until weaning with 13 or 14 sows per treatment. Fecal samples were collected upon entry into the farrowing 
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house (approximately d 110 of gestion) and prior to weaning (approximately d 18 post-farrowing). Data reported as 
geometric mean of MIC ± SEM. 
 
2 Yeast-based pre- and probiotics included Actisaf Sc 47 HR+ at 0.10% and SafMannan at 0.025% (Phileo by 
Lesaffre, Milwaukee, WI) from d 110 of gestation until weaning. 
3 The MIC numerator of the ratio was reported for the antimicrobial’s amoxicillin:clavulanic acid 2:1 ratio and 
trimethoprim/sulfamethoxazole 1:19 ratio. 
4 Interaction of diet × day where sows fed a control diet had lower (P = 0.035) MIC to cefoxitin at weaning compared 
to sows fed yeast additives. There were no evidence for treatment differences (P = 0.237) observed at the entry into the 






Table 2-5. Main effects of including live yeast and a yeast extract in lactation diets and time of sample collection on antimicrobial susceptibilities of 
fecal Escherichia coli  in sows according to National Antimicrobial Resistance Monitoring System (CLSI, 2018) established breakpoints1 
Antimicrobial Control Yeast2 P = Entry Wean P = 
Amoxicillin:clavulanic acid 2:1 ratio3 8.8 ± 1.1 9.1 ± 1.1 0.854 4.0 ± 0.40 20.1 ± 3.27 < 0.001 
Ampicillin 10.2 ± 1.5 8.1 ± 1.2 0.276 3.4 ± 0.47 24.7 ± 3.52 < 0.001 
Azithromycin 5.5 ± 0.58 6.1 ± 0.66 0.318 4.9 ± 0.56 6.9 ± 0.81 0.016 
Cefoxitin 11.0 ± 1.1 13.4 ± 1.4 0.186 6.9 ± 0.6 21.4 ± 2.8 < 0.001 
Ceftiofur 1.5 ± 0.18 1.6 ± 0.20 0.822 0.45 ± 0.058 5.33 ± 0.693 < 0.001 
Ceftriaxone 1.6 ± 0.43 1.7 ± 0.46 0.919 0.30 ± 0.052 9.41 ± 2.962 < 0.001 
Chloramphenicol 8.6 ± 0.56 9.4 ± 0.62 0.338 8.8 ± 0.67 9.2 ± 0.71 0.742 
Ciprofloxacin 0.027 ± 0.0043 0.032 ± 0.0052 0.491 0.019 ± 0.0012 0.047 ± 0.0112 0.002 
Gentamicin 0.98 ± 0.076 0.95 ± 0.075 0.774 1.00 ± 0.079 0.93 ± 0.062 0.268 
Nalidixic acid 3.1 ± 0.59 3.9 ± 0.78 0.369 2.4 ± 0.22 4.9 ± 1.21 0.009 
Streptomycin 16.0 ± 2.3 17.3 ± 2.5 0.657 12.5 ± 2.0 22.2 ± 3.6 0.017 
Sulfisoxazole 190 ± 27 186 ± 27 0.912 168 ± 30 210 ± 26 0.345 
Tetracycline 16.4 ± 2.6 18.4 ± 2.9 0.618 11.0 ± 2.1 27.3 ± 2.8 < 0.001 
Trimethoprim/sulfamethoxazole 1:19 ratio3 0.19 ± 0.039 0.25 ± 0.053 0.366 0.14 ± 0.017 0.34 ± 0.099 0.010 
1 A total of 27 mixed-parity sows (DNA 241, DNA Genetics) and litters were used in a lactation study from d 110 of gestation until weaning with 13 or 14 
sows per treatment. Fecal samples were collected upon entry into the farrowing house (approximately d 110 of gestation) and prior to weaning (approximately d 
18 post-farrowing). Data reported as geometric mean of MIC ± SEM. 
2 Yeast-based pre- and probiotics included Actisaf Sc 47 HR+ at 0.10% and SafMannan at 0.025% (Phileo by Lesaffre, Milwaukee, WI) from d 110 of 
gestation until weaning. 




CHAPTER 3- The effect of live yeast and yeast extracts included in 1 
lactation diets on sow and litter performance and antimicrobial 2 
susceptibility of fecal Escherichia coli: II Nursery performance 3 
 4 
 Abstract 5 
Two experiments were conducted to determine the impact of various combinations of 6 
yeast-based direct fed microbials (DFM) in diets fed to nursery pigs weaned from sows fed 7 
lactation diets with or without yeast additives. In Exp. 1, 340 weaned pigs, initially 5.1 kg ± 0.02, 8 
were used to evaluate previous sow treatment (control vs yeast additives) and nursery diets with 9 
or without added yeast-based DFM on growth performance and antimicrobial resistance (AMR) 10 
patterns of fecal Escherichia coli. Treatments were arranged in a 2 × 2 factorial with main effects 11 
of sow treatment (control vs. yeast-based pre- and probiotic diet; 0.10% ActiSaf Sc 47 HR+ and 12 
0.025% SafMannan, Phileo by Lesaffre, Milwaukee, WI) and nursery treatment (control vs. 13 
yeast-based pre- and probiotic diet; 0.10% ActiSaf Sc 47 HR+, 0.05% SafMannan, and 0.05% 14 
NucleoSaf from d 0 to 7, then concentrations were decreased by 50% from d 7 to 24) with 5 pigs 15 
per pen and 17 replications per treatment. Progeny from sows fed yeast additives had increased 16 
(P < 0.05) average daily gain (ADG) from d 0 to 24 and d 0 to 45. However, pigs that were fed 17 
yeast additives for the first 24 d in the nursery tended to have decreased d 0 to 45 ADG (P = 18 
0.079). Fecal E.coli isolated from pigs from the sows fed yeast group had increased (P = 0.034) 19 
AMR to nalidixic acid and a tendency for increased AMR to ciprofloxacin (P = 0.065) and 20 
gentamicin (P = 0.054). Yet, when yeast additives were added in the nursery there was reduced 21 
(P < 0.05) fecal E.coli AMR to azithromycin and chloramphenicol. In Exp. 2, 330 weaned pigs, 22 
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initially 5.8 kg ± 0.03, were used to evaluate diets with two different combinations of DFM on 23 
growth performance. Treatments were arranged in a 2 × 3 factorial with main effects of sow 24 
treatment (same as described in Exp. 1) and nursery treatment (control; DFM 1, 0.05% of 25 
SafMannan from d 0 to 38 and NucleoSaf at 0.05% from d 0 to 10 and 0.025% from d 10 to 24; 26 
or DFM 2, 0.10% MicroSaf from d 0 to 38 and NucleoSaf at 0.05% from d 0 to 10 and 0.025% 27 
from d 10 to 24) with 6 pigs per pen and 8 to 10 replications per treatment. From d 0 to 10 post-28 
weaning, progeny of sows fed yeast additives had increased (P < 0.05) ADG and feed efficiency. 29 
In conclusion, feeding sows yeast through lactation improved offspring growth performance in 30 
the nursery. While feeding live yeast and yeast extracts reduced nursery pig performance in Exp. 31 
1, feeding DFM 2 improved growth later in the nursery period in Exp. 2.  32 
 33 
 34 
Key Words: Antimicrobial resistance, Bacillus, growth, live yeast, nursery pigs, yeast extract  35 
 36 
 37 
 Abbreviations 38 
ADFI: Average daily feed intake 39 
ADG: Average daily gain 40 
AMR: Antimicrobial resistance 41 
ATCC: American Type Culture Collection 42 
BW: Body weight 43 
CFU: Colony-forming unit 44 
CLSI: Clinical and Laboratory Standards Institute 45 
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CP: Crude protein 46 
DFM: Direct-fed microbial 47 
ETEC: Enterotoxigenic E.coli 48 
G:F: Gain-to-feed ratio/feed efficiency 49 
ME: Metabolizable energy 50 
MIC: Minimal inhibitory concentration  51 
NARMS: National Antimicrobial Resistance Monitoring System  52 
NRC: National Research Council 53 
NE: Net energy 54 
PCR: Polymerase chain reaction 55 
PWD: Post-weaning diarrhea  56 
SCFA: Short-chain fatty acid 57 
SEM: Standard error of the mean 58 
SID: Standardized ileal digestible 59 
STTD: Standardized total tract digestible 60 




The post-weaning period is one of the most stressful periods in a pig’s life. Separation 
from the sow, transitioning from a liquid to solid diet, and a new environment with new pen-
mates are contributing factors that lead to the post-weaning growth lag and diarrhea (PWD; 
Pluske, 2013). During this time, it is common for the colonization of enterotoxigenic E.coli 
(ETEC) in the gut which is one of the main causes for PWD (Fairbrother et al., 2005).  
Antibiotics were used for many years to help control the occurrences of PWD caused by ETEC; 
however, the ban of antibiotics for growth promotion purposes in the EU in 2006 (Regulation 
(EC) No. 1831/2003) and the implementation of the veterinary feed directive in the US in 2017 
(FD&C Act (21 U. S. C. 354 (a) (1))) have led to research in alternative strategies to help 
mitigate the negative effects that follow weaning.   
Yeast-based pre- and probiotics, also known as direct fed microbials (DFM), have been 
considered an alternative of interest because of their potential to positively modulate gut 
microflora which may lead to improved immunity, nutrient digestion and absorption, and growth 
performance (Liao and Nyachoti, 2017; Menegat et al., 2019b). These beneficial attributes may 
be heightened during a stressful stage of life, such as weaning. Supplementing live yeast 
(Saccharomyces cerevisiae) and/or yeast extracts derived from S. cerevisiae following weaning 
has alleviated the shedding of ETEC, shortened diarrhea occurrences, and improved nursery 
body weight (BW; Stuyven et al., 2009; Trckova et al., 2014). Lu et al. (2019) recently reported 
that feeding S. cerevisiae through gestation and lactation improved ADG, increased BW, and 
improved gross energy digestibility of offspring in the nursery.  
There is little data exploring the impacts of feeding live yeast and yeast extracts in late 
gestation through lactation and its impact on subsequent offspring growth performance and 
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antimicrobial susceptibilities of fecal E.coli in the nursery. Our hypothesis was that the addition 
of yeast-based DFM would provide additive growth, from both the sow and nursery 
supplementation, and may lessen the instances of antimicrobial resistance (AMR) of antibiotics 
that are meaningful to human and animal medicine in nursery pigs. 
 
 Materials and Methods  
 General 
The Kansas State University Institutional Animal Care and Use Committee approved the 
protocols used in two experiments to evaluate various yeast-based DFM supplementation when 
pigs were weaned from sows fed a diet with or without yeast additives. Both studies were 
conducted at the Kansas State University Swine Teaching and Research Center in Manhattan, 
KS. A single nursery room was used in Exp. 1 and Exp. 2 was conducted between two identical 
nursery rooms. All nursery rooms utilized are completely enclosed, environmentally controlled, 
and mechanically ventilated. Each pen contained a 4-hole, dry self-feeder and a nipple waterer to 
provide ad libitum access to feed and water. Pens (1.3  1.3 m) had metal tri-bar floors and 
allowed approximately 0.34 m2/pig in Exp. 1 and 0.28 m2/pig in Exp. 2.  
 
 Experiment 1 
Animals and treatment structure. The objective of Exp. 1 was to evaluate the live yeast 
S. cerevisiae strain NCYC Sc 47 and yeast-based prebiotics derived from S. cerevisiae on 
nursery pigs weaned from sows fed a diet with or without yeast additives on growth performance 
and antimicrobial susceptibilities of E.coli isolated from nursery pig fecal matter. A total of 340 
weaned pigs (DNA 241 × 600, DNA; initially 5.1 ± 0.03 kg BW), offspring of sows fed either a 
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control diet or a diet containing yeast-based pre- and probiotics from d 110 of gestation through 
weaning, were used in a 45-d nursery study (Chance et al., 2021b). Only ten weaned pigs (7 from 
control litters and 3 from yeast additive litters) were not included in the nursery study to maintain 
an even number of replications per treatment and/or because of poor health. Pigs within the same 
sow treatment were kept together and allotted to pens, pens were then allotted to treatment with 5 
pigs per pen and 17 replications per treatment in a completely randomized design.  
Dietary treatments were arranged in a 2 × 2 factorial with main effects of sow treatment 
(control vs. yeast additives; 0.10% ActiSaf Sc 47 HR+ and 0.025% SafMannan; Phileo by 
Lesaffre, Milwaukee, WI) and nursery treatment (control vs. yeast additives; 0.10% ActiSaf Sc 
47 HR+, 0.05% SafMannan, and 0.05% NucleoSaf from d 0 to 7 then concentrations were 
lowered by 50% from d 7 to 24). Thus, half of the pigs from each sow group was fed either a 
control diet or a diet with yeast additives. The live yeast Saccharomyces cerevisiae strain NCYC 
Sc 47 (ActiSaf Sc 47 HR+) served as the yeast-based probiotic. The yeast-based prebiotics 
included a yeast cell wall fraction with concentrated mannan-oligosaccharides and β-glucans 
from S. cerevisiae (SafMannan) and a yeast extract containing ≥ 6% unbound nucleotides from 
S. cerevisiae (NucleoSaf). 
Diet preparation. Pigs were fed experimental phase 1 diets from placement until d 7 and 
then offered experimental phase 2 diets from d 7 to 24 (Table 3-1). A common phase 3 diet 
without live yeast or yeast extracts was fed to all pigs from d 24 to 45 (Table 3-1). Phase 1 diets 
were formulated to 1.40% standardized ileal digestible (SID) Lys and phase 2 and 3 diets were 
formulated to 1.35% SID Lys. All other nutrients were formulated to meet or exceed National 
Research Council (NRC, 2012) requirement estimates. Phase 1 and 2 diets were manufactured at 
the Kansas State University O.H. Kruse Feed Technology Innovation Center (Manhattan, KS) 
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and the common phase 3 diet was manufactured by a commercial feed mill (Hubbard Feeds; 
Beloit, KS). All three phases were fed in meal form. Pens of pigs were weighed, and feed 
disappearance recorded weekly during the course of this study to determine average daily gain 
(ADG), average daily feed intake (ADFI), and gain-to-feed ratio (G:F). 
Chemical analysis. Phase 1 and 2 diet samples were collected at manufacturing and 
phase 3 diets were collected from every fourth 23 kg bag using a feed probe to obtain a 
representative sample for each respective diet and phase. Complete diet samples were stored at -
20C until they were homogenized, subsampled, and submitted for analysis. Samples per dietary 
treatment were analyzed (Analabs; Fulton, IL; method 997.02; AOAC International, 1998) for 
active live yeast in phase 1 (Control: 2,000 CFU/g vs. Yeast: 19,000,000 CFU/g) and phase 2 
(Control: 1,000 CFU/g vs. Yeast: 8,000,000 CFU/g) diets.  
Fecal collection. Fecal samples were collected on d 5, 24, and 45 of the experiment for 
fecal antimicrobial resistance profiles of E.coli. Fecal samples were collected directly from the 
rectum of the same three randomly selected pigs from each pen and pooled by pen to form one 
composite sample. Fecal samples were collected using a sterile, single-use cotton tipped 
applicator (Fisher Healthcare, Pittsburgh, PA) and were stored in a clean, single-use zipper 
storage bag and kept on ice until delivered to the laboratory on the same day of collection. Fecal 
samples were transported to the laboratory at the Kansas State University College of Veterinary 
Medicine for bacterial isolation and further characterization. 
E.coli isolation and antimicrobial susceptibility testing. Fecal samples were subjected 
to the culture method, as described in chapter 2 (Chance et al., 2021b), to isolate and identify E 
coli. Antimicrobial susceptibility testing was conducted on one E.coli isolate per fecal sample 
recovered on days 5, 24, and 45. Briefly, the microbroth dilution method as outlined by the 
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Clinical and Laboratory Standards Institute (CLSI, 2018: Table 1-3) was used to determine the 
minimal inhibitory concentrations (MIC) of antibiotics. Clinical and Laboratory Standards 
Institute guidelines were used to classify each isolate as susceptible, intermediate, or resistant 
according to the breakpoints established for each antimicrobial. Minimal inhibitory concentration 
values greater than the susceptible breakpoint but lower than the resistant breakpoint were 
considered intermediate. The antimicrobials evaluated included: amoxicillin/clavulanic acid 2:1 
ratio, ampicillin, azithromycin, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, 
gentamicin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and 
trimethoprim/sulfamethoxazole. 
 
 Experiment 2  
Animals and treatment structure. The objective of Exp. 2 was to evaluate feeding diets 
with two different combinations of Bacillus spp. and yeast extracts derived from S. cerevisiae on 
nursery pigs weaned from sows fed a diet with or without yeast additives on nursery pig growth 
performance. A total of 330 weaned pigs (DNA 241 × 600, DNA; initially 5.8 ± 0.03 kg BW), 
progeny of sows fed either a control diet or a diet containing yeast additives from d 110 of 
gestation through weaning, were used in a 38-d nursery study (Chance et al., 2021b). Only 
twelve weaned pigs (6 pigs from each sow treatment) were not included in the nursery study due 
to being either a fall behind needing extra care or pigs that were well above the average weight at 
weaning. Pigs within the same sow treatment were randomly allotted to pens, pens were then 
allotted to treatment with 6 pigs per pen and 8 to 10 replications per treatment. 
  Dietary treatments were fed in 3 phases and arranged in a 2 × 3 factorial with main 
effects of sow treatment (control vs. yeast additives; 0.10% ActiSaf Sc 47 HR+ and 0.025% 
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SafMannan; Phileo by Lesaffre, Milwaukee, WI) and nursery treatment (control; DFM 1, 0.05% 
of SafMannan from d 0 to 38 and NucleoSaf at 0.05% from d 0 to 10 and 0.025% from d 10 to 
24; or DFM 2, 0.10% MicroSaf from d 0 to 38 and NucleoSaf at 0.05% from d 0 to 10 and 
0.025% from d 10 to 24; SafMannan, NucleoSaf, and MicroSaf; Phileo by Lesaffre, Milwaukee, 
WI). Thus, one third of the pigs from each sow group were fed either a control diet, a diet with 
the DFM 1 additives, or a diet with the DFM 2 additives. Direct fed microbial 1 included a yeast 
cell wall fraction with concentrated mannan-oligosaccharides and β-glucans from S. cerevisiae 
(SafMannan) and DFM 2 included a blend of Bacillus spp. and a yeast cell wall fraction 
(MicroSaf). Both DFM 1 and DFM 2 included a yeast extract containing ≥ 6% unbound 
nucleotides from S. cerevisiae (NucleoSaf). A respiratory disease challenge occurred from 
approximately d 8 to 20 of the study; thus, removals were recorded and analyzed (Table 3-6 & 3-
7).  
Diet preparation. Pigs were fed phase 1 diets from placement until d 10, phase 2 diets 
were fed from d 10 to 24, and phase 3 diets fed from d 24 to 38 (Table 3-1). Phase 1 diets were 
formulated to 1.40% SID Lys and phase 2 and 3 diets were formulated to 1.35% SID Lys. All 
other nutrients were formulated to meet or exceed NRC (2012) requirement estimates. The phase 
1 control diet was manufactured by a commercial feed mill (Hubbard Feeds; Beloit, KS) then 
DFM 1 and DFM 2 were added at their respective amounts for phase 1 and mixed at the O.H. 
Kruse Feed Technology Innovation Center (Manhattan, KS). All phase 2 and 3 diets were 
manufactured by the same commercial feed mill with the DFM added at the expense of corn. 
Feed samples were collected from every fourth, 23 kg bag using a feed probe to obtain a 
representative sample for each respective diet and phase. All three phases were fed in meal form. 
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Pens of pigs were weighed, and feed disappearance recorded weekly to determine ADG, ADFI 
and G:F.  
 
 Statistical analysis 
  In both experiments, growth performance data were analyzed using the nlme package of 
R (Version 4.0.0, R Foundation for Statistical Computing, Vienna, Austria) as a completely 
randomized design with pen as the experimental unit. Fixed effects included sow treatment, 
nursery treatment, and their interaction. Nursery room served as the random effect in Exp. 2. The 
main effects of sow treatment and nursery treatment, as well as their interactions, were tested. In 
Exp. 2, the proportion of pigs removed from test pens was analyzed using a binomial distribution 
using a logit link function. Differences between treatments were considered significant at P ≤ 
0.05 and marginally significant at 0.05 < P ≤ 0.10. 
In Exp. 1, the MIC data of each antimicrobial was analyzed using a linear mixed model. 
Fixed effects of the model included sow diet, nursery pig diet, sampling day, and their second- 
and third-order interactions. Pen was included in the model as a random effect. The variance-
covariance structure of pen was taken as either compound symmetry, first-order autoregressive 
or unstructured according to the model fitting criteria. To better satisfy model assumptions, data 
underwent natural log transformation before statistical modeling. Treatment effect was assessed 
via back-transformed least squares means, i.e. geometric means of the MIC values. Statistical 
analysis was performed using Statistical Analysis Software (SAS version 9.4; Cary, NC) PROC 
MIXED with option DDFM=KR in the MODEL statement. Comparisons were carried out using 




 Results  
 Experiment 1 
Growth Performance. There were no interactions observed between sow treatment and 
nursery treatment for any growth performance criteria (Table 3-2). In phase 1 (d 0 to 7), there 
were no main effects (P > 0.30) observed for ADG, ADFI, or G:F for sow or nursery treatments 
(Table 3-2 & 3-3). Pigs weaned from sows fed the yeast-based pre- and probiotics entered the 
nursery at a heavier BW (P < 0.001; 5.0 vs 5.2 kg) compared to offspring from the control sows. 
There was statistical difference (P < 0.001) in d 7 BW with offspring from sows fed the yeast-
based pre- and probiotics having a heavier BW at the end of phase 1.  
In phase 2 (d 7 to 24) and for the overall experimental period (d 0 to 24), progeny from 
sows fed the yeast-based pre- and probiotics had increased (P < 0.05) ADG, ADFI, and d 24 
BW; however, there was no evidence for difference (P = 0.162) in G:F. There was no statistical 
difference (P > 0.10) observed for nursery dietary treatment on any growth criteria. 
  During the common period (d 24 to 45), there were main effects (P < 0.05) of both sow 
and nursery treatments on ADG. Offspring from sows fed the yeast-based pre- and probiotics 
had increased (P = 0.003) ADG, heavier (P < 0.001) d 45 BW, and a tendency (P = 0.057) for 
increased ADFI compared to progeny from sows fed the control diet. Pigs fed the control diet in 
the nursery had increased (P = 0.011) ADG and a tendency (P = 0.060) for increased ADFI 
compared to those fed the diet containing live yeast and yeast extracts. There was no evidence 
for statistical difference (P > 0.10) in G:F for sow or nursery treatment.  
For the overall period (d 0 to 45), progeny from sows fed the yeast-based products had 
increased (P < 0.05) BW, ADG, ADFI, and improved G:F compared to pigs from sows fed the 
control diet. There was a tendency for increased (P = 0.079) ADG and increased (P = 0.086) BW 
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for pigs fed the control diet in the nursery compared to those fed the yeast-based pre- and 
probiotics. There was no statistical difference (P > 0.10) in ADFI or G:F for nursery treatment.   
Antimicrobial Susceptibilities. A three-way interaction of sow treatment × nursery 
treatment × sampling day was observed (P < 0.05) for ciprofloxacin, gentamicin, sulfisoxazole, 
and trimethoprim/sulfamethoxazole (Table 3-4). E.coli isolated from feces of pigs from sows fed 
yeast additives and fed yeast-based pre- and probiotics through the nursery had reduced (P = 
0.044) MIC values to ciprofloxacin on d 45 with a tendency (P = 0.081) for reduced AMR on d 
24 compared to pigs from the same sow treatment group but fed a control nursery diet. However, 
there was evidence for a marginal increase (P = 0.061) in MIC values of E.coli to ciprofloxacin 
on d 5 from progeny of sows fed yeast which were also fed live yeast and yeast extracts in the 
nursery. For gentamicin, MIC values of fecal E.coli isolated from pigs of the yeast sow and yeast 
nursery treatment were higher (P = 0.021) on d 5 but lower (P = 0.018) on d 24 compared to the 
yeast sow and control nursery treatment. On d 45, E.coli isolated from feces collected from 
progeny of the control sows that were then fed yeast-based pre- and probiotics in the nursery had 
lower (P = 0.005) MIC values to sulfisoxazole compared to pigs that were also from the control 
sow group but fed a control diet in the nursery. Fecal E.coli had lower (P = 0.004) MIC values 
on d 5 to trimethoprim/sulfamethoxazole from the control sow and yeast nursery treatment 
compared to the control sow and control nursery treatment. It is important to note that all fecal 
E.coli isolates had  lower MIC values for ciprofloxacin, gentamicin, sulfisoxazole, and 
trimethoprim/sulfamethoxazole and thus, all values would be classified as susceptible for each 
respective antimicrobial. There were no further three- or two-way interactions observed; thus, the 
main effects of sow treatment, nursery treatment, and sampling day were explored (Table 3-5).  
65 
 
The dams of the pigs used in this study had increased (P < 0.001) fecal E.coli AMR to 
tetracycline at weaning compared to at the entry into the farrowing house, regardless of dietary 
treatment (Chance et al., 2021b). Interestingly, this effect carried over into the nursery. All fecal 
E.coli isolates had significantly (P < 0.001) higher MIC values to tetracycline on d 5 post-
weaning which then decreased on d 24 and then slightly increased on d 45. No matter the dietary 
treatment combination, all E.coli isolated were resistant to tetracycline on d 5 but were 
intermediate on d 24 and 45. Fecal E.coli isolates were considered susceptible or intermediate for 
the remaining 13 antimicrobials at all three sampling timepoints (d 5, 24, and 45) regardless of 
the sow or nursery dietary inclusion of live yeast and yeast extracts.  
E.coli isolated from feces of the progeny of sows fed yeast-based pre- and probiotics had 
increased (P = 0.034) MIC values to nalidixic acid and a tendency for increased AMR to 
ciprofloxacin (P = 0.065) and gentamicin (P =0.054). Fecal E.coli isolates had reduced AMR to 
azithromycin (P = 0.037) and chloramphenicol (P = 0.031) when live yeast and yeast extracts 
were supplemented in the nursery. Again, all fecal E.coli isolates would be classified as 
susceptible or intermediate for each respective antimicrobial as tetracycline was the only 
antibiotic that displayed resistance in this study.  
There was evidence for decreased (P < 0.05) AMR over time in fecal E.coli for 
azithromycin, cefoxitin, and streptomycin regardless of yeast-based pre- and probiotic 
supplementation in the sow or nursery treatment. Axomicillin:clavulanic acid, chloramphenicol, 
and trimethoprim/sulfamethoxazole had increased (P < 0.10) MIC values from d 5 to 24 and then 
reduced MIC values from d 24 to 45. This differs from gentamicin, nalidixic acid, and 
tetracycline which had reduced (P < 0.10) AMR from d 5 to 24 and then an increase in MIC 
values from d 24 to 45. 
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 Experiment 2 
There were no interactions observed between previous sow treatment and nursery 
treatment (Table 3-6). Thus, the main effects of sow and nursery treatment are reported (Table 3-
7).  
In phase 1 (d 0 to 10), pigs weaned from sows fed yeast additives had increased (P < 0.03) ADG, 
ADFI, and G:F. Offspring from the sows fed yeast additives had lighter BW at weaning (P < 
0.001) compared to the control sow’s progeny; however, by d 10 there was no difference (P = 
0.753) in nursery pig BW between the two sow treatments. There was no evidence for difference 
(P > 0.10) for nursery dietary treatment on any growth criteria from d 0 to 10. In phase 2 (d 10 to 
24), there was no evidence (P > 0.10) for difference for either sow or nursery treatments on any 
of the response criteria. 
In phase 3 (d 24 to 38), there was a tendency (P = 0.090) for increased ADFI for progeny 
of sows that were fed the control diet. There was no difference (P > 0.10) for previous sow 
treatment on ADG, G:F, or d 38 BW. Interestingly, pigs fed the DFM 2 treatment in the nursery 
had increased (P < 0.05) ADG, G:F, and d 38 BW compared to the control treatment with pigs 
fed DFM 1 intermediate.  
For the overall period (d 0 to 38), a tendency (P = 0.080) was observed for improved G:F 
of offspring from sows fed yeast additives from d 110 of gestation through weaning. As 
mentioned previously, pigs fed the DFM 2 treatment in the nursery had greater (P < 0.05) ending 
BW compared to the control treatment with pigs fed DFM 1 intermediate. Regardless of dietary 
treatment, there was no difference (P > 0.05) in ADG or ADFI for the overall period. There was 
no evidence for statistical difference (P > 0.10) for the percentage of removals between 




Probiotics are beneficial, live microorganisms that are designed to withstand the acidic 
pH of the stomach and once in the gastrointestinal tract can manipulate its microbial population. 
Probiotics increase the desirable microbes in the gut while subsequently out-competing enteric 
pathogens, which can lead to increased short-chain fatty acid (SCFA) production, improved 
intestinal lining integrity, increased nutrient absorption, and ultimately improved growth (Liao 
and Nyachoti, 2017; Liu et al., 2017; Cameron and McAllister, 2019). Most probiotics are often 
classified as: Bacillus, lactic acid producing bacteria (Lactobacillus, Bifidobacterium, and 
Pediococcus) or yeast (S. cerevisiae; Stein and Kil, 2006; Cameron and McAllister, 2019). 
Although similar to probiotics, prebiotics are not live microorganisms. Instead, prebiotics 
function as a food source, through fermentation and further SCFA production, to selectively 
stimulate the favorable gut microorganisms (Gibson et al., 2004). Inulin, lactulose, fructo-
olgosaccharides, and transgalacto-oligosaccharides can be easily fermented; thus, they are some 
of the most commonly used prebiotics in nursery pig diets (Gibson et al., 2004; Liu et al; 2017).   
In Exp. 1, live S. cerevisiae strain NCYC Sc 47 was evaluated as the yeast-based 
probiotic (ActiSaf Sc 47 HR+; Phileo by Lesaffre, Milwaukee, WI). We evaluated two yeast-
based prebiotics in both Exp. 1 and Exp. 2, which included a yeast cell wall fraction with 
concentrated mannan-oligosaccharides and β-glucans (SafMannan; Phileo by Lesaffre, 
Milwaukee, WI) and a yeast extract containing ≥ 6% unbound nucleotides (NucleoSaf; Phileo by 
Lesaffre, Milwaukee, WI). The unique qualities of live yeast and yeast extracts is partially due to 
the β-glucans and α-mannans in the yeast cell wall and the fact that they encompass free 
nucleotides. Some of the benefits from feeding nursery pigs live yeast (probiotic) and yeast 
extracts (prebiotic) include: enhanced immunity (Perez-Sotelo et al., 2011; Zanello et al., 2011; 
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Badia et al., 2012), minimized ETEC challenges (Kiarie et al., 2011; Che et al., 2017; Trevisi et 
al., 2017), adsorption of mycotoxins in the feed (Kogan and Kocher, 2007), and increased 
growth (Shen et al., 2009; Kiros et al., 2018). 
 In Exp. 2, DFM 1 contained the same yeast extracts as in Exp. 1 (SafMannan and 
NucleoSaf) but did not contain a probiotic source. Direct fed microbial 2 contained a blend of 
Bacillus spp. and yeast extracts (MicroSaf and NucleoSaf; Phileo by Lesaffre, Milwaukee, WI). 
Bacillus-based probiotics are Gram-positive, spore-forming organisms that can withstand the 
acidic pH of the stomach and high temperatures of pelleting making them one of the most 
utilized probiotics in swine diets (Stein and Kil, 2006). Bacillus spores are active at the more 
neutral pH of the small intestine allowing for a higher likelihood for colonization and production 
of enzymes leading to an increase in SCFAs (Liu et al., 2017). Increasing SCFA production in a 
young pig can lower the digesta pH which helps control enteric pathogens and can lead to 
reduced occurrences of PWD (Liao and Nyachoti, 2017; Liu et al., 2017). 
Although feeding pre- and probiotics has promising results on growth performance in the 
nursery, there is still inconsistency in literature (Zimmerman et al., 2016). Many studies have 
observed increased ADG, ADFI, and BW when live S. cerevisiae and yeast extracts were fed in 
the nursery (Shen et al., 2009; Kiarie et al., 2011; Kiros et al., 2018). In contrast, we observed 
reduced ADG during the common (d 24 to 45) and overall (d 0 to 45) periods with little 
statistical impact on any of the remaining growth criteria when pigs were fed the live yeast S. 
cerevisiae and yeast extracts in Exp.1. Similarly, there was no difference in growth performance 
criteria when pigs were fed only yeast extracts (DFM 1) compared to pigs fed a control diet in 
Exp. 2. Like our findings, feeding live yeast and/or yeast extracts did not affect nursery pig 
growth performance in some studies (Perez-Sotelo et al., 2011; Trevisi et al., 2015; and Williams 
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et al., 2016). When pigs were fed a Bacillus spp. and yeast extract blend (DFM 2) they had 
improved ADG and G:F in phase 3 (d 24 to 38) and heavier end of nursery BW. When Lee et al. 
(2011) fed a yeast-Bacillus blend for 35 d post-weaning, they saw no added growth benefit from 
the inclusion of the probiotic blend.  
Some literature does not report improvement in ADG, ADFI, or BW when Bacillus was 
included in nursery diets (Williams et al., 2018; Menegat et al., 2019a; Wang et al., 2021); 
however, other studies report an improvement in G:F in the early nursery period (Cai et al., 
2015; Wang et al, 2021). A possible explanation for the improvement in some growth 
performance criteria in Exp. 2 for DFM 2 could be because there was a synergistic effect of the 
Bacillus spp. and the yeast cell wall fraction (MicroSaf), without the inclusion of the unbound 
nucleotides (NucleoSaf), which resulted in an improvement in the later nursery period, regardless 
of sow treatment. The results from both experiments further exemplifies the variability in results 
when feeding pre- and probiotics in the nursery.   
Some studies have observed an increase in sow ADFI during lactation when yeast 
products were included in the diet (Chance et al., 2021b, Tan et al., 2021). It is generally 
observed that when sows have increased intake during lactation, they tend to wean heavier pigs 
(Eissen et al., 2003; Krahn et al., 2021). Even though Chance et al. (2021b) and Tan et al. (2021) 
observed increased sow ADFI in lactation, they did not observe an improvement in litter or 
individual pig weaning weight. However, feeding sows yeast additives has shown to improve 
offspring immunity (Zanello et al., 2012; Gao et al., 2021), increase exposure to beneficial 
microorganisms through the sow feces (Hasan et al., 2018), and increase growth pre-weaning 
(Kim et al., 2008; Shen et al., 2011). These benefits may allow for the offspring to be more 
physiologically prepared for the stressful weaning period. In the present study, pigs were weaned 
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from sows that were fed the live yeast S. cerevisiae strain NCYC Sc 47 (ActiSaf HR+; Phileo by 
Lesaffre, Milwaukee, WI) which served as the yeast-based probiotic from entry into the 
farrowing house (approximately d 110 of gestation) through lactation. A yeast cell wall fraction 
with concentrated mannan-oligosaccharides and β-glucans derived from Saccharomyces 
cerevisiae (SafMannan; Phileo by Lesaffre, Milwaukee, WI) was also fed and considered a 
yeast-based prebiotic.   
The immunological and microfloral benefits observed pre-weaning may be the main 
contributing factors to the improvement in growth post-weaning as a few studies have observed 
improved growth in the nursery when pigs were weaned from sows fed yeast. Both Lu et al. 
(2019) and Loughmiller et al. (2021) reported increased ADG and ADFI in the nursery when 
pigs were weaned from sows that were fed live yeast through gestation and lactation, which is 
consistent with the results from d 0 to 24 and d 0 to 45 in Exp. 1 and d 0 to 10 in Exp. 2. Both of 
the present experiments showed the potential for improved G:F when pigs were weaned from 
sows supplemented with yeast which was consistent with Lu et al. (2019) but not observed by 
Loughmiller et al. (2021).  
 To our knowledge, there is no data following the offspring of sows fed a lactation diet 
with or with yeast on the antimicrobial resistance of gut bacteria. A sow treatment × nursery 
treatment × sampling day interaction was observed for gentamicin in the current study. This 
interaction revealed fecal E.coli from progeny of yeast-fed sows that were also fed yeast in the 
nursery had higher MIC on d 5 post-weaning but lower MIC on d 24 compared to pigs from the 
yeast-fed sows but fed a control diet in the nursery. Furthermore, offspring of sows fed yeast 
tended to have increased AMR to gentamicin than offspring of sows fed the control diet in the 
farrowing house. It is important to note that, while there were statistical differences, all fecal 
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E.coli were considered susceptible to gentamicin. Gentamicin is an aminoglycoside class 
antimicrobial, and its key function is to target the 30s ribosomal subunit to prevent protein 
synthesis (Yoshizawa et al., 1998). It is commonly used to treat Gram-negative infections but 
can also be used to treat a select few Gram-positive bacteria in both humans and animals. 
 Ciprofloxacin and nalidixic acid are in the fluoroquinolone antibiotic family. 
Ciprofloxacin is used as broad-spectrum antimicrobial and nalidixic acid is used to treat 
primarily Gram-negative infections (Crumplin and Smith, 1975; Davis et al., 1996). Both 
antibiotics are used in human medicine; however, neither are utilized in animal agriculture. 
Fluoroquinolone class antibiotics prevent bacteria DNA synthesis by inhibiting the DNA gyrase 
enzyme ultimately resulting in cell death (Paton and Reeves, 1988). We observed a sow 
treatment × nursery treatment × sampling day interaction for ciprofloxacin. Fecal E.coli of 
offspring of yeast-fed sows that were fed yeast in the nursery appeared to have higher MIC on d 
24 and 45 but lower MIC on d 5 compared to pigs also weaned from sows fed yeast but were fed 
the control diet in the nursery. Furthermore, progeny of sows fed yeast in the farrowing house 
tended to have increased AMR to ciprofloxacin and nalidixic acid. However, regardless of sow 
treatment, all fecal E.coli were considered susceptible to ciprofloxacin and nalidixic acid at all 
sampling time points.  
 Sulfisoxazole and trimpethorim/sulfamethoxazole are in the sulfonamide antimicrobial 
class. They are broad-spectrum antibiotics and both inhibit the dihydropteroate enzyme during 
folic acid metabolism which normally aids in nucleic acids production for DNA (Kapoor et al., 
2017). Sulfisoxazole and trimpethorim/sulfamethoxazole are commonly used antibiotics in both 
human and livestock medicine. A sow treatment × nursery treatment × sampling day interaction 
was observed for both sulfisoxazole and trimpethorim/sulfamethoxazole in our study. Progeny of 
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the control sows that were fed live yeast and yeast extracts in the nursery had lower MIC values 
to sulfisoxazole on d 45 and to trimpethorim/sulfamethoxazole on d 5 compared to offspring that 
were also from the control sows but were fed a control diet in the nursery. Once again, all fecal 
E.coli was susceptible to both sulfisoxazole and trimpethorim/sulfamethoxazole regardless of 
treatment or sampling day.  
Azithromycin is in the azalide family, a more specific class of macrolide antimicrobials 
(Bakheit et al., 2014). Chloramphenicol is a partially synthesized antibiotic from Streptomyces 
venequelae in the phenicol class (National Center for Biotechnology Information, 2021). Both 
azithromycin and chloramphenicol are broad-spectrum antibiotics that interfere with protein 
synthesis by binding to the 50s ribosomal subunit resulting in bacterial cell death (Bakheit et al., 
2014; National Center for Biotechnology Information, 2021). However, azithromycin is 
commonly utilized in both humans and animals while chloramphenicol is rarely used in human 
medicine and prohibited in animal agriculture. We observed a decrease in MIC values for the 
antimicrobial’s azithromycin and chloramphenicol in nursery pig fecal E.coli when live yeast 
and yeast extracts were included in the diet. All MIC values were well under the CLSI (2018) 
breakpoint for azithromycin and chloramphenicol and were considered either susceptible or 
intermediate. Adversely, the addition of the same combination of live yeast and yeast extracts 
used in Exp. 1 did not impact the AMR of fecal E.coli in nursery pigs in chapter 1 (Chance et al., 
2021a). Using the same 14 antimicrobials evaluated in our study, Williams et al. (2018) also 
observed no difference in the AMR of fecal E.coli from nursery pigs that were fed a bacillus-
based DFM or a blend of lactic acid producing DFM compared to pigs fed a control diet. 
In conclusion, for Exp. 1, when sows were fed a live yeast and yeast extract from d 110 
of gestation through weaning, their progeny were heavier at weaning and had increased ADG, 
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ADFI, and heavier BW throughout the nursery period. However, feeding yeast additives in the 
nursery tended to reduce ADG and lower nursery ending BW. Offspring from sows that were fed 
yeast might increase the potential of fecal E.coli AMR to nalidixic acid, ciprofloxacin, and 
gentamicin. Yet, feeding live yeast and yeast extracts in the nursery may lessen the AMR of 
azithromycin and chloramphenicol of fecal E.coli. In Exp. 2, feeding yeast additives from d 110 
of gestation through lactation improved progeny nursery growth performance from d 0 to 10 
post-weaning and tended to improve overall G:F. Additionally, feeding DFM 2 in nursery diets 
improved final BW and late nursery ADG and G:F compared to pigs not fed a DFM. Thus, in 
Exp. 2, the addition of yeast additives in sow diets had more impact on offspring’s growth 
performance in the early nursery while the inclusion of DFMs in the nursery had more influence 





Table 3-1. Diet composition (as-fed basis)1,2 
 Exp. 1  Exp. 2  
 Item Phase 1 Phase 2 Phase 3  Phase 1 Phase 2 Phase 3 
Ingredients, %    
 
    
   Corn 44.36 57.40 64.73  44.15 56.75 64.75 
   Soybean meal, 46.5% CP 18.12 26.35 31.30  18.20 25.85 31.30 
   Whey powder 25.00 10.00 ---  25.00 10.00 --- 
   Fish meal  4.50 --- ---  4.50 2.00 --- 
   Enzymatically-treated soybean meal3 3.75 2.00 ---  3.75 --- --- 
   Oil 1.50 --- ---  1.50 1.50 --- 
   Calcium carbonate 0.30 0.90 0.85  0.30 0.63 0.85 
   Monocalcium phosphate, 21% P 0.48 1.10 1.00  0.48 0.85 1.00 
   Salt 0.30 0.55 0.60  0.30 0.55 0.60 
   L-Lys-HCl 0.43 0.51 0.52  0.43 0.51 0.52 
   DL-Met 0.22 0.22 0.21  0.22 0.22 0.21 
   L-Thr 0.18 0.21 0.22  0.18 0.22 0.22 
   L-Trp 0.07 0.06 0.06  0.07 0.06 0.06 
   L-Val 0.13 0.14 0.13  0.13 0.15 0.13 
   L-Ile --- --- ---  --- 0.02 --- 
   Vitamin premix4  0.25 0.25 ---  --- --- --- 
   Vitamin premix with phytase5 --- --- 0.25  0.25 0.25 0.25 
   Trace mineral premix6 0.15 0.15 0.15  0.15 0.15 0.15 
   Zinc oxide --- --- ---  0.40 0.27 --- 
   Phytase7 0.08 0.08 ---  --- --- --- 
   DFM 8,9 ± ± ---  ± ± ± 




Table 3-1. (cont.) 
 Exp. 1  Exp. 2  
  Phase 1 Phase 2 Phase 3   Phase 1 Phase 2 Phase 3 
Calculated analysis     
  
 
SID amino acids, %     
  
 
   Lys  1.40 1.35 1.35  1.40 1.35 1.35 
   Ile:Lys 56 55 55  56 55 55 
   Leu:Lys 109 112 114  109 110 114 
   Met:Lys 38 36 36  38 37 36 
   Met and Cys:Lys 57 57 57  57 57 57 
   Thr:Lys 63 63 63  63 63 63 
   Trp:Lys 20.6 20.2 20.3  20.6 20.0  20.3 
   Val:Lys 69 69 69  69 69 69 
   His:Lys 32 34 36  32 34 36 
Total Lys, % 1.54 1.48 1.49  1.54 1.49 1.49 
ME, kcal/kg 3,425 3,282 3,278  3,419 3,373 3,280 
NE, kcal/kg 2,582 2,440 2,421  2,577 2,529 2,423 
SID Lys:NE, g/Mcal 5.42 5.53 5.57  5.43 5.34 5.57 
CP, % 20.9 20.5 21.2  20.9 20.3 21.2 
Ca, % 0.69 0.77 0.69  0.69 0.70 0.69 
P, % 0.68 0.66 0.61  0.68 0.64 0.61 
STTD P, % 0.63 0.58 0.50  0.63 0.57 0.50 
1 In Exp. 1, phase 1 diets were fed from d 0 to 7 (approximately 5.1 to 5.5 kg BW) and phase 2 diets were fed 
from d 7 to 24 (approximately 5.5 to 11.9 kg BW). A common diet, without yeast additives, was fed during phase 3 
from d 24 to 45 (approximately 11.9 to 27.1 kg BW). 
2 In Exp. 2, phase 1 diets were fed from d 0 to 10 (approximately 5.8 to 6.7 kg BW), phase 2 diets were fed from d 
10 to 24 (approximately 6.7 to 13.3 kg BW), and phase 3 diets were fed from d 24 to 38 (approximately 13.3 to 21.5 
kg BW).  
3 HP 300, Hamlet Protein, Findlay, OH. 
4 Provided per kg of premix: 1,653,465 IU vitamin A; 661,386 IU vitamin D; 17,637 IU vitamin E; 1,322 mg 
vitamin K; 13.2 mg vitamin B12; 19,841 mg niacin; 11,023 mg pantothenic acid; 3,307 mg riboflavin. 
5 Ronozyme HiPhos GT 2700 (DSM Nutritional Products, Parsippany, NJ) provided 2,027 FTU/kg in phases 1 
and 2 and 1,250 FTU/kg in phase 3 with an expected STTD P release of 0.16% in phases 1 and 2 and 0.14% in 
phase 3. Provided per kg of premix: 1,653,465 IU vitamin A; 661,386 IU vitamin D; 17,637 IU vitamin E; 1,322 mg 
vitamin K; 13.2 mg vitamin B12; 19,841 mg niacin; 11,023 mg pantothenic acid; 3,307 mg riboflavin. 
6 Provided per kg of premix: 73 g Zn from Zn sulfate; 73 g Fe from iron sulfate; 22 g Mn from manganese oxide; 
11 g Cu from copper sulfate; 0.2 g I from calcium iodate; 0.2 g Se from sodium selenite. 
7 Ronozyme HiPhos 2700 (DSM Nutritional Products, Parsippany, NJ) provided 918 FTU/lb and an estimated 
release of 0.16% STTD P.  
8 In Exp. 1, DFM included 0.10% ActiSaf Sc 47 HR+, 0.05% SafMannan, and 0.05% NucleoSaf in phase 1 diets 
and then concentrations were lowered by 50% in phase 2 diets (Phileo by Lesaffre, Milwaukee, WI). 
9 In Exp 2, DFM 1 was a yeast-extract blend with SafMannan (0.05% in phases 1, 2, and 3) and NucleoSaf (0.05% 
in phase 1, 0.025% in phase 2 and 0% in phase 3) or DFM 2 was a Bacillus spp. and yeast-extract blend with 
MicroSaf (0.10% in phases 1, 2, and 3) and NucleoSaf (0.05% in phase 1, 0.025% in phase 2 and 0% in phase 3). 
SafMannan, NucleoSaf, and MicroSaf; Phileo by Lesaffre, Milwaukee, WI.  
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Table 3-2. Exp.1– Interactive effects of yeast-fed sows and yeast-fed nursery pigs on growth performance of nursery pigs1 
 Sow treatment2/Nursery treatment3   
 Control  Yeast  P = 
Item Control Yeast   Control Yeast SEM Sow  Nursery 
Sow × 
Nursery 
BW, kg          
   d 0 5.02 4.97  5.21 5.21 0.034 < 0.001 0.507 0.507 
   d 7 5.40 5.34  5.62 5.59 0.070 0.001 0.516 0.825 
   d 24 11.51 11.38  12.33 12.22 0.211 < 0.001 0.569 0.968 
   d 45 26.54 26.18  28.23 27.35 0.356 < 0.001 0.086 0.476 
Phase 1 (d 0 to 7)         
   ADG, g 54 46  53 53 7.9 0.719 0.604 0.654 
   ADFI, g 113 113  122 116 6.4 0.351 0.585 0.637 
   G:F, g/kg 464 368  397 415 56.9 0.858 0.497 0.315 
Phase 2 (d 7 to 24)         
   ADG, g 359 354  390 387 9.7 0.002 0.653 0.920 
   ADFI, g 499 493  535 523 14.6 0.026 0.530 0.864 
   G:F, g/kg 722 719  732 742 11.4 0.162 0.781 0.580 
Experimental period (d 0 to 24)         
   ADG, g 269 263  291 288 8.1 0.006 0.560 0.839 
   ADFI, g 386 380  413 403 11.4 0.031 0.479 0.822 
   G:F, g/kg 701 690  705 717 10.8 0.153 0.974 0.308 
Phase 3 common diet (d 24 to 45)        
   ADG, g 716 700  754 721 9.6 0.003 0.011 0.369 
   ADFI, g 1,085 1,059  1,122 1,086 16.3 0.057 0.060 0.747 
   G:F, g/kg 660 661  673 664 5.2 0.123 0.446 0.337 
Overall (d 0 to 45)         
   ADG, g 477 465  504 489 7.4 0.001 0.079 0.868 
   ADFI, g 711 695  739 720 12.3 0.037 0.163 0.940 
   G:F, g/kg 671 670  683 680 5.1 0.040 0.599 0.862 
1 A total of 340 pigs (initial BW of 5.1 ± 0.03 kg) were used in a 45-d nursery trial with 5 pigs per pen and 17 pens per treatment. Pigs were 
weaned at approximately 19 d of age and allotted to treatment in completely randomized design. Dietary treatments were arranged in a 2 × 2 





2 Sow treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with ActiSaf Sc 47 HR+ at 0.10% 
and SafMannan at 0.025% (Phileo by Lesaffre, Milwaukee, WI) from d 110 of gestation until weaning.  
3 Nursery treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with 0.10% ActiSaf Sc 47 HR+, 




Table 3-3. Exp.1– Main effects of yeast-fed sows and yeast-fed nursery pigs on growth performance of nursery pigs1 
 Sow treatment
2   Nursery treatment
3   
Item Control Yeast SEM P = Control Yeast SEM P = 
BW, kg         
   d 0 5.00 5.21 0.024 < 0.001 5.11 5.09 0.024 0.507 
   d 7 5.37 5.61 0.049 0.001 5.51 5.46 0.049 0.516 
   d 24 11.44 12.27 0.149 < 0.001 11.92 11.80 0.149 0.569 
   d 45 26.36 27.79 0.251 < 0.001 27.38 26.76 0.251 0.086 
Phase 1 (d 0 to 7)         
   ADG, g 50 53 5.6 0.719 54 50 5.6 0.604 
   ADFI, g 113 119 4.5 0.351 118 114 4.5 0.585 
   G:F, g/kg 416 406 40.2 0.858 430 391 40.2 0.497 
Phase 2 (d 7 to 24)         
   ADG, g 357 388 6.8 0.002 375 370 6.8 0.653 
   ADFI, g 496 529 10.3 0.026 517 508 10.3 0.530 
   G:F, g/kg 721 737 8.1 0.162 727 730 8.1 0.781 
Experimental period (d 0 to 24)        
   ADG, g 266 289 5.7 0.006 280 275 5.7 0.560 
   ADFI, g 383 408 8.0 0.031 400 391 8.0 0.479 
   G:F, g/kg 695 711 7.6 0.153 703 703 7.6 0.974 
Phase 3 common diet (d 24 to 45)        
   ADG, g 708 738 6.8 0.003 735 710 6.8 0.011 
   ADFI, g 1,072 1,103 11.5 0.057 1,104 1,072 11.5 0.060 
   G:F, g/kg 661 669 3.7 0.123 667 663 3.7 0.446 
Overall (d 0 to 45)        
   ADG, g 471 496 5.2 0.001 490 477 5.2 0.079 
   ADFI, g 703 729 8.7 0.037 725 708 8.7 0.163 
   G:F, g/kg 671 681 3.6 0.040 677 675 3.6 0.599 
1 A total of 340 pigs (initial BW of 5.1 ± 0.03 kg) were used in a 45-d nursery trial with 5 pigs per pen and 34 pens per treatment. Pigs were 
weaned at approximately 19 d of age and allotted to treatment in completely randomized design. Dietary treatments were arranged in a 2 × 2 
factorial with main effects of sow treatment (control or yeast additives) and nursery pig treatment (control or yeast additives).  
2 Sow treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with ActiSaf Sc 47 HR+ at 0.10% 
and SafMannan at 0.025% (Phileo by Lesaffre, Milwaukee, WI) from d 110 of gestation until weaning.  
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3 Nursery treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with 0.10% ActiSaf Sc 47 
HR+, 0.05% SafMannan, and 0.05% NucleoSaf in phase 1 diets and then concentrations were lowered by 50% in phase 2 diets (Phileo by 





Table 3-4. Exp. 1– Interactive effects of yeast-fed sows and yeast-fed nursery pigs over time on antimicrobial susceptibilities of nursery pig fecal Escherichia coli 
according to National Antimicrobial Resistance Monitoring System (CLSI, 2018) established breakpoints1,2 
 Sow treatment2/Nursery treatment3   
 Control  Yeast  P = 










Amoxicillin:clavulanic acid 2:1 ratio5     0.455 0.389 0.024 0.389 0.438 0.656 0.849 
   d 5 4.9 ± 1.1 5.1 ± 1.1  6.3 ± 1.3 6.0 ± 1.3         
   d 24 6.8 ± 1.5 8.0 ± 1.7  10.2 ± 2.2 8.0 ± 1.7         
   d 45 6.8 ± 1.5 5.5 ± 1.2  6.3 ± 1.3 4.5 ± 1.0         
Ampicillin      0.925 0.85 0.191 0.220 0.697 0.226 0.856 
   d 5 7.7 ± 2.2 9.0 ± 2.5  7.7 ± 2.2 7.4 ± 2.1         
   d 24 7.4 ± 2.1 11.1 ± 3.1  10.2 ± 2.9 12.0 ± 3.4         
   d 45 7.7 ± 2.2 6.8 ± 1.9  9.0 ± 2.5 4.3 ± 1.2         
Azithromycin      0.291 0.037 0.034 0.480 0.484 0.909 0.328 
   d 5 5.1 ± 0.46 5.1 ± 0.46  5.3 ± 0.48 4.5 ± 0.41         
   d 24 4.5 ± 0.32 4.0 ± 0.28  4.5 ± 0.32 4.5 ± 0.32         
   d 45 4.2 ± 0.24 4.0 ± 0.23  4.9 ± 0.28 4.2 ± 0.24         
Cefoxitin      0.434 0.372 0.006 0.823 0.352 0.543 0.781 
   d 5 10.2 ± 2.0 8.3 ± 1.6  9.4 ± 1.8 9.8 ± 1.9         
   d 24 8.0 ± 1.5 8.0 ± 1.5  10.6 ± 2.1 11.1 ± 2.1         
   d 45 7.4 ± 1.4 6.0 ± 1.2  7.4 ± 1.4 5.3 ± 1.0         
Ceftiofur      0.438 0.877 0.962 0.485 0.708 0.374 0.073 
   d 5 0.96 ± 0.30 0.64 ± 0.20  0.69 ± 0.22 1.70 ± 0.53         
   d 24 0.92 ± 0.29 0.88 ± 0.28  0.96 ± 0.30 1.08 ± 0.34         
   d 45 0.92 ± 0.29 0.92 ± 0.29  1.28 ± 0.40 0.61 ± 0.19         
Ceftriaxone      0.687 0.762 0.279 0.481 0.194 0.519 0.509 
   d 5 0.42 ± 0.19 0.48 ± 0.21  0.82 ± 0.36 1.13 ± 0.50         
   d 24 1.04 ± 0.46 1.13 ± 0.50  0.96 ± 0.43 0.88 ± 0.39         
   d 45 0.69 ± 0.31 0.78 ± 0.35  0.96 ± 0.43 0.33 ± 0.15         
Chloramphenicol      0.299 0.031 <0.001 0.136 0.966 0.180 0.701 
   d 5 9.0 ± 0.97 7.1 ± 0.76  9.0 ± 0.97 6.5 ± 0.70         
   d 24 9.4 ± 1.01 11.1 ± 1.19  10.2 ± 1.09 8.7 ± 0.93         
   d 45 7.4 ± 0.79 7.1 ± 0.76  7.4 ± 0.79 6.3 ± 0.67                 






Table 3-4. (cont.) 
 Sow treatment2/Nursery treatment3   
 Control  Yeast   P = 










Ciprofloxacin6       0.065 0.557 0.790 0.291 0.419 0.495 0.010 
   d 5 0.020 ± 0.0043 0.015 ± 0.0032  0.018 ± 0.0040 0.033 ± 0.0071         
   d 24 0.015 ± 0.0032 0.017 ± 0.0037  0.029 ± 0.0062 0.017 ± 0.0037         
   d 45 0.018 ± 0.0038 0.025 ± 0.0053  0.028 ± 0.0060 0.015 ± 0.0032         
Gentamicin7       0.054 0.638 < 0.001 0.736 0.379 0.065 0.045 
   d 5 0.96 ± 0.210 0.89 ± 0.194  0.96 ± 0.210 2.00 ± 0.437         
   d 24 0.48 ± 0.086 0.48 ± 0.086  0.72 ± 0.129 0.39 ± 0.070         
   d 45 0.72 ± 0.071 0.61 ± 0.060  0.78 ± 0.077 0.67 ± 0.065         
Nalidixic acid       0.034 0.648 0.075 0.648 0.061 0.551 0.201 
   d 5 2.0 ± 0.45 2.0 ± 0.45  3.1 ± 0.71 4.2 ± 0.94         
   d 24 2.2 ± 0.13 2.1 ± 0.13  2.4 ± 0.15 2.1 ± 0.13         
   d 45 2.2 ± 0.35 3.0 ± 0.49  2.9 ± 0.47 2.5 ± 0.40         
Streptomycin       0.493 0.600 < 0.001 0.444 0.147 0.391 0.393 
   d 5 14.2 ± 3.23 21.3 ± 4.86  13.1 ± 2.98 16.0 ± 3.65         
   d 24 7.1 ± 2.56 12.5 ± 4.53  11.6 ± 4.17 8.3 ± 3.01         
   d 45 6.5 ± 1.68 4.7 ± 1.21  9.0 ± 2.32 9.0 ± 2.32         
Sulfisoxazole8       0.881 1.000 0.363 0.159 0.989 0.416 0.035 
   d 5 67 ± 20 78 ± 24  69 ± 21 85 ± 26         
   d 24 48 ± 15 64 ± 20  57 ± 17 57 ± 17         
   d 45 109 ± 33 32 ± 10  44 ± 14 78 ± 24         
Tetracycline       0.540 0.624 < 0.001 0.223 0.580 0.985 0.645 
   d 5 25.1 ± 3.7 30.7 ± 4.5  26.1 ± 3.9 18.8 ± 2.8         
   d 24 6.8 ± 1.5 7.4 ± 1.7  8.3 ± 1.9 6.5 ± 1.5         
   d 45 8.7 ± 2.1 8.3 ± 2.0  8.3 ± 2.0 8.3 ± 2.0         
Trimethoprim/sulfamethoxazole 1:19 ratio5,9     0.781 0.304 0.069 0.973 0.415 0.208 0.042 
   d 5 0.42 ± 0.126 0.12 ± 0.036  0.24 ± 0.074 0.24 ± 0.074         
   d 24 0.28 ± 0.083 0.37 ± 0.111  0.30 ± 0.091 0.21 ± 0.063         
   d 45 0.12 ± 0.036 0.18 ± 0.055  0.22 ± 0.068 0.18 ± 0.055                 
1 A total of 340 pigs (initially 5.1 ± 0.03 kg) were used in a 45-d nursery trial with 5 pigs per pen and 17 pens per treatment. Pigs were weaned at  
approximately19 d of age and allotted to treatment in completely randomized design. Dietary treatments were arranged in a 2 × 2 factorial with main effects of  




 2 Fecal samples from the same 3 pigs/pen were collected on d 5, 24, & 45. 
3 Sow treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with ActiSaf Sc 47 HR+ at 0.10% and SafMannan at 0.025%  
(Phileo by Lesaffre, Milwaukee, WI) from d 110 of gestation until weaning. Sow fecal samples were collected on ~ d 110 of gestation and d 18 post-farrowing. 
 4 Nursery treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with 0.10% ActiSaf Sc 47 HR+, 0.05% SafMannan, and 
0.05% NucleoSaf in phase 1 diets and then concentrations were lowered by 50% in phase 2 diets (Phileo by Lesaffre, Milwaukee, WI). 
 5 The MIC numerator of the ratio was reporter for the antimicrobial’s amoxicillin:clavulanic acid 2:1 ratio and trimethoprim/sulfamethoxazole 1:19 ratio. 
6 A three-way interaction of sow treatment × nursery treatment × day was observed (P = 0.010). On d 24 (P = 0.081) and on d 45 (P = 0.044), pigs that were fed yeast 
in the nursery and came from the yeast sow group having reduced MIC values compared to nursery pigs fed a control diet who were also reared from sows fed yeast. 
There was marginal evidence on d 5 (P = 0.061) for the yeast sow group offspring fed yeast additives having increased MIC values compared to pigs fed a control diet 
who were also offspring of sows fed yeast. 
7 A three-way interaction of sow treatment × nursery treatment × day was observed (P = 0.045). MIC values of fecal E.coli isolated from pigs of the yeast sow and 
yeast nursery treatment being higher (P = 0.021) on d 5 but lower (P = 0.018) on d 24 compared to the yeast sow and control nursery treatment. There was no evidence for 
difference (P > 0.10) between dietary treatments on d 45. 
8 A three-way interaction of sow treatment × nursery treatment × day was observed (P = 0.035).  On d 45, pigs that came from the control sow treatment and yeast 
nursery treatment had lower (P = 0.005) MIC values compared to pigs that were also from the control sow group but fed a control diet in the nursery. There was no 
evidence for difference (P > 0.10) between dietary treatments on d 5 or d 24. 
9 A three-way interaction of sow treatment × nursery treatment × day was observed (P = 0.042). On d 5, pigs that came from the control sow treatment and yeast 
nursery treatment had lower (P = 0.004) MIC values compared to the control sow and control nursery treatment. There was no evidence for difference (P > 0.10) between 




Table 3-5. Exp. 1– Main effects of yeast-fed sows, yeast-fed nursery pigs, and sampling time on antimicrobial susceptibilities of nursery pig fecal Escherichia coli 
according to National Antimicrobial Main Resistance Monitoring System (CLSI, 2018) established breakpoints1,2 
 Sow treatment
3  Nursery treatment
4  Day  
Item Control Yeast P = Control Yeast P = 5 24 45 P = 
Amoxicillin:clavulanic 
acid 2:1 ratio5 
6.1 ± 0.51 6.7 ± 0.55 0.455 6.7 ± 0.56 6.1 ± 0.50 0.389 5.5 ± 0.59a 8.2 ± 0.87b 5.7 ± 0.61a 0.024 
Ampicillin 8.2 ± 0.83 8.1 ± 0.82 0.925 8.2 ± 0.83 8.0 ± 0.81 0.850 7.9 ± 1.1 10.0 ± 1.4 6.7 ± 0.9 0.191 
Azithromycin 4.5 ± 0.12 4.7 ± 0.13 0.291 4.7 ± 0.13 4.4 ± 0.12 0.037 5.0 ± 0.23b 4.4 ± 0.16a 4.3 ± 0.12a 0.034 
Cefoxitin 7.9 ± 0.67 8.7 ± 0.74 0.434 8.7 ± 0.75 7.8 ± 0.67 0.372 9.4 ± 0.91b 9.3 ± 0.90b 6.5 ± 0.62a 0.006 
Ceftiofur 0.87 ± 0.11 0.99 ± 0.12 0.438 0.94 ± 0.12 0.92 ± 0.11 0.877 0.92 ± 0.14 0.96 ± 0.15 0.90 ± 0.14 0.962 
Ceftriaxone 0.71 ± 0.14 0.79 ± 0.15 0.687 0.78 ± 0.15 0.72 ± 0.14 0.762 0.66 ± 0.15 1.00 ± 0.22 0.65 ± 0.14 0.279 



















Gentamicin 0.67 ± 0.047 0.81 ± 0.058 0.054 0.75 ± 0.053 0.72 ± 0.051 0.638 1.13 ± 0.124c 0.51 ± 0.045a 0.69 ± 0.034b < 0.001 
Nalidixic acid 2.2 ± 0.16 2.8 ± 0.20 0.034 2.4 ± 0.18 2.5 ± 0.19 0.648 2.7 ± 0.30b 2.2 ± 0.07a 2.6 ± 0.21b 0.075 
Streptomycin 9.7 ± 1.1 10.9 ± 1.3 0.493 9.8 ± 1.2 10.7 ± 1.3 0.600 15.8 ± 1.8b 9.6 ± 1.7a 7.1 ± 0.9a < 0.001 
Sulfisoxazole 61.9 ± 7.9 63.6 ± 8.1 0.881 62.7 ± 8.0 62.7 ± 8.0 1.000 74.6 ± 11.4 56.1 ± 8.6 59.0 ± 9.0 0.363 
Tetracycline 11.9 ± 0.93 11.1 ± 0.87 0.540 11.8 ± 0.92 11.2 ± 0.87 0.624 24.8 ± 1.83b 7.2 ± 0.82a 8.4 ± 1.03a < 0.001 
Trimethoprim/ 
Sulfamethoxazole5 
0.22 ± 0.028 0.23 ± 0.029 0.781 0.25 ± 0.031 0.20 ± 0.026 0.304 0.23 ± 0.035b 0.28 ± 0.043b 0.17 ± 0.026a 0.069 
1 A total of 340 pigs (initially 5.1 ± 0.03 kg BW) were used in a 45-d nursery trial with 5 pigs per pen and 34 pens per treatment. Pigs were weaned at approximately 
19 d of age and allotted to treatment in completely randomized design. Dietary treatments were arranged in a 2 × 2 factorial with main effects of sow treatment (control 
or yeast additives) and nursery pig treatment (control or yeast additives). Data reported as geometric mean of MIC ± SEM. 
2 Fecal samples from the same 3 pigs/pen were collected on d 5, 24, & 45.  
3 Sow treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with ActiSaf Sc 47 HR+ at 0.10% and SafMannan at 
0.025%  
(Phileo by Lesaffre, Milwaukee, WI) from d 110 of gestation until weaning.  Sow fecal samples were collected on ~ d 110 of gestation and d 18 post-farrowing. 
4 Nursery treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with 0.10% ActiSaf Sc 47 HR+, 0.05% SafMannan, and 
0.05% NucleoSaf in phase 1 diets and then concentrations were lowered by 50% in phase 2 diets (Phileo by Lesaffre, Milwaukee, WI). 
 5 The MIC numerator of the ratio was reporter for the antimicrobial’s amoxicillin:clavulanic acid 2:1 ratio and trimethoprim/sulfamethoxazole. 




Table 3-6. Exp. 2– Interactive effects of yeast-fed sows and DFM-fed nursery pigs on growth performance of nursery pigs1  
 Sow treatment2/Nursery treatment   
 Control  Yeast  P = 
Item Control DFM 13 DFM 24   Control DFM 1 DFM 2 SEM Sow  Nursery Sow × Nursery 
BW, kg            
   d 0 5.91 5.90 5.90  5.64 5.65 5.61 0.032 < 0.001 0.738 0.722 
   d 10 6.52 6.77 6.73  6.66 6.64 6.64 0.112 0.753 0.498 0.399 
   d 24 12.90 13.34 13.37  13.11 13.42 13.40 0.254 0.591 0.206 0.930 
   d 38 20.99 21.62 21.89  20.98 21.79 21.95 0.371 0.800 0.028 0.969 
Phase 1 (d 0 to 10)            
   ADG, g 60 82 82  101 99 101 10.7 0.003 0.508 0.428 
   ADFI, g 114 138 130  142 156 156 9.6 0.002 0.103 0.850 
   G:F, g/kg 491 596 623  697 624 644 47.5 0.023 0.680 0.081 
Phase 2 (d 10 to 24)            
   ADG, g 441 469 464  454 457 470 12.7 0.815 0.235 0.559 
   ADFI, g 560 611 598  584 589 610 17.4 0.738 0.117 0.333 
   G:F, g/kg 788 468 777  778 777 771 10.8 0.750 0.548 0.530 
Phase 3 (d 24 to 38)           
   ADG, g 578 592 608  562 598 599 13.6 0.553 0.033 0.685 
   ADFI, g 895 896 908  856 891 878 18.6 0.090 0.533 0.613 
   G:F, g/kg 645 660 671  656 672 684 11.4 0.179 0.064 0.992 
Overall (d 0 to 38)            
   ADG, g 383 412 411  399 408 411 10.5 0.596 0.094 0.599 
   ADFI, g 555 591 581  565 577 576 13.7 0.811 0.730 0.632 
   G:F, g/kg 690 697 707  706 708 714 8.4 0.069 0.307 0.809 
Removals, % 7.4 1.7 5.6   2.1 7.4 10.0 3.87 0.625 0.402 0.179 
1 A total of 330 pigs (initially 5.8 ± 0.03 kg BW) were used in a 38-d nursery trial with 6 pigs per pen and 8 to 10 pens per treatment. Pigs were weaned at 
approximately 19 d of age and allotted to treatment in completely randomized design. Dietary treatments were arranged in a 2 × 3 factorial with main effects of sow 
treatment (control or yeast additives) and nursery pig treatment (control, DFM 1, or DFM 2).  
2 Sow treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with Actisaf Sc 47 HR+ at 0.10% and SafMannan at 
0.025% (Phileo by Lesaffre, Milwaukee, WI) from d 110 of gestation until weaning.  
3 DFM 1 was a yeast-extract blend with SafMannan (0.05% in phases 1, 2, and 3) and NucleoSaf (0.05% in phase 1, 0.025% in phase 2 and 0% in phase 3); Phileo 




4 DFM 2 was a Bacillus spp. and yeast-extract blend with MicroSaf (0.10% in phases 1, 2, and 3) and NucleoSaf (0.05% in phase 1, 0.025% in phase 2 and 0% in 
phase 3); Phileo by Lesaffre, Milwaukee, WI.  
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Table 3-7. Exp. 2– Main effects of yeast-fed sows and DFM-fed nursery pigs on growth performance of nursery pigs1 
 Sow treatment
2   Nursery treatment   
Item Control Yeast SEM P = Control DFM 13 DFM 24 SEM P = 
BW, kg          
   d 0 5.90 5.64 0.017 < 0.001 5.78 5.77 5.76 0.022 0.738 
   d 10 6.67 6.65 0.061 0.753 6.59 6.71 6.69 0.077 0.498 
   d 24 13.21 13.31 0.139 0.591 13.01 13.38 13.39 0.174 0.206 
   d 38 21.50 21.57 0.203 0.800 20.98b 21.71ab 21.92a 0.255 0.028 
Phase 1 (d 0 to 10)         
   ADG, g 75 100 5.9 0.003 81 90 92 7.4 0.508 
   ADFI, g 127 151 5.2 0.002 128 147 143 6.6 0.103 
   G:F, g/kg 570 655 26.0 0.023 594 610 634 32.7 0.680 
Phase 2 (d 10 to 24)         
   ADG, g 458 460 7.0 0.815 447 463 467 8.7 0.235 
   ADFI, g 590 594 9.5 0.738 572 600 604 11.9 0.117 
   G:F, g/kg 778 775 5.9 0.772 783 773 774 7.5 0.547 
Phase 3 (d 24 to 38)         
   ADG, g 592 586 7.4 0.553 570b 595ab 604a 9.3 0.033 
   ADFI, g 900 875 10.2 0.090 876 893 893 12.8 0.533 
   G:F, g/kg 659 670 6.3 0.191 651b 666ab 677a 7.9 0.057 
Overall (d 0 to 38)         
   ADG, g 402 406 5.8 0.596 391 410 411 7.2 0.094 
   ADFI, g 575 573 7.5 0.811 560 584 579 9.4 0.173 
   G:F, g/kg 698 709 4.6 0.080 698 703 711 5.7 0.276 
Removals, % 4.1 5.4 2.08 0.625 4.0 3.6 7.5 2.54 0.402 
1 A total of 330 pigs (initially 5.8 ± 0.03 kg BW) were used in a 38-d nursery trial with 6 pigs per pen and 16 to 20 pens per treatment. Pigs were 
weaned at approximately 19 d of age and allotted to treatment in completely randomized design. Dietary treatments were arranged in a 2 × 3 factorial 
with main effects of sow treatment (control or yeast additives) and nursery pig treatment (control, DFM 1, or DFM 2).  
2 Sow treatment consisted of providing a control diet or a yeast-based pre- & probiotic diet supplemented with Actisaf Sc 47 HR+ at 0.10% and 
SafMannan at 0.025% (Phileo by Lesaffre, Milwaukee, WI) from d 110 of gestation until weaning.  
3 DFM 1 was a yeast-extract blend with SafMannan (0.05% in phases 1, 2, and 3) and NucleoSaf (0.05% in phase 1, 0.025% in phase 2 and 0% in 
phase 3); Phileo by Lesaffre, Milwaukee, WI. 
4 DFM 2 was a Bacillus spp. and yeast-extract blend with MicroSaf (0.10% in phases 1, 2, and 3) and NucleoSaf (0.05% in phase 1, 0.025% in 
phase 2 and 0% in phase 3); Phileo by Lesaffre, Milwaukee, WI. 
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